<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml" xmlns:art="http://www.rsc.org/schema/rscart38" xmlns:epub="http://www.idpf.org/2007/ops" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:rsc="urn:rsc.org" xml:lang="en" lang="en"><head><!--Google Tag Manager--><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&amp;l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-56FZ7G');</script><!--End Google Tag Manager--><title>Tailoring morphologies of mesoporous polydopamine nanoparticles to deliver high-loading radioiodine for anaplastic thyroid carcinoma imaging and thera ...  - Nanoscale (RSC Publishing) DOI:10.1039/D1NR02892H</title><link rel="canonical" href="https://pubs.rsc.org/en/content/articlehtml/2021/nr/d1nr02892h"/><meta http-equiv="content-type" content="application/xhtml+xml; charset=utf-8"/><script type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"NRJS-aaa897feae8feeca979","applicationID":"1313546638","transactionName":"M1wANxQFCEcDVU0PWgoWLzUlSyVbDEJcCEEnVgwXFAsKWAdEFgdHEFABDwMMElkO","queueTime":0,"applicationTime":491,"agent":"","atts":""}</script><script type="text/javascript">(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"1386013924",accountID:"2851366",trustKey:"1029994",xpid:"Vg4CUFVVDhABV1BRAgUBUFcJ",licenseKey:"NRJS-aaa897feae8feeca979",applicationID:"1313546638"};;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */
(()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}const p={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},m={};function v(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!m[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return m[e]}function b(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");m[e]=(0,i.D)(t,p),(0,n.Qy)(e,m[e],"loader_config")}const y=(0,n.mF)().o;var w=r(385),x=r(6818);const A={buildEnv:x.Re,bytesSent:{},queryBytesSent:{},customTransaction:void 0,disabled:!1,distMethod:x.gF,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,offset:Math.floor(w._A?.performance?.timeOrigin||w._A?.performance?.timing?.navigationStart||Date.now()),onerror:void 0,origin:""+w._A.location,ptid:void 0,releaseIds:{},session:void 0,xhrWrappable:"function"==typeof w._A.XMLHttpRequest?.prototype?.addEventListener,version:x.q4},E={};function T(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!E[e])throw new Error("Runtime for ".concat(e," was never set"));return E[e]}function _(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");E[e]=(0,i.D)(t,A),(0,n.Qy)(e,E[e],"runtime")}function D(e){return function(e){try{const t=s(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}(e)}},9567:(e,t,r)=>{r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u<s.length;++u)f(s[u],c);(0,i.D)(c,(function(e,t){(0,i.D)(t,(function(t,r){r[0].on(e,r[1])}))}))}delete a[t],r.backlog[t]=null,r.emit("drain-"+t,[])}}r.every((e=>{let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;f<d;f++)s[f].apply(a,r);var l=T()[c[e]];return l&&l.push([p,e,r,a]),a}}function b(e,t){n[e]=w(e).concat(t)}function y(e,t){var r=n[e];if(r)for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)}function w(e){return n[e]||[]}function x(t){return f[t]=f[t]||e(p,t)}function A(e,t){var r=T();p.aborted||(0,o.D)(e,(function(e,n){t=t||"feature",c[n]=t,t in r||(r[t]=[])}))}function E(e){return!!T()[c[e]]}function T(){return p.backlog}}(void 0,"globalEE"),c.ee=u)},5546:(e,t,r)=>{r.d(t,{E:()=>n,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s<e;s++)a.push(o(r,++i).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},7056:(e,t,r)=>{r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c<t.length;c++)d(a=e[s=t[c]])||(e[s]=r(a,u?s+n:n,i,s,o))},r.flag=i,r;function r(t,r,n,a,s){return d(t)?t:(r||(r=""),nrWrapper[i]=t,u(t,nrWrapper,e),nrWrapper);function nrWrapper(){var i,u,d,f;try{u=this,i=[...arguments],d="function"==typeof n?n(i,u):n||{}}catch(t){c([t,"",[i,u,a],d],e)}o(r+"start",[i,u,a],d,s);try{return f=t.apply(u,i)}catch(e){throw o(r+"err",[i,u,e],d,s),e}finally{o(r+"end",[i,u,f],d,s)}}}function o(r,n,i,o){if(!a||t){var s=a;a=!0;try{e.emit(r,n,i,t,o)}catch(t){c([t,r,n,i],e)}a=s}}}function c(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function u(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){c([e],r)}for(var n in e)o.call(e,n)&&(t[n]=e[n]);return t}function d(e){return!(e&&e instanceof Function&&e.apply&&!e[i])}var f=r(2210),l=r(385);const h={},g=XMLHttpRequest,p="addEventListener",m="removeEventListener";function v(e){var t=function(e){return(e||n.ee).get("events")}(e);if(h[t.debugId]++)return t;h[t.debugId]=1;var r=s(t,!0);function i(e){r.inPlace(e,[p,m],"-",o)}function o(e,t){return e[1]}return"getPrototypeOf"in Object&&(l.il&&b(document,i),b(l._A,i),b(g.prototype,i)),t.on(p+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,f.X)(n,"nr@wrapped",(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(m+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function b(e,t){let r=e;for(;"object"==typeof r&&!Object.prototype.hasOwnProperty.call(r,p);)r=Object.getPrototypeOf(r);for(var n=arguments.length,i=new Array(n>2?n-2:0),o=2;o<n;o++)i[o-2]=arguments[o];r&&t(r,...i)}var y="fetch-",w=y+"body-",x=["arrayBuffer","blob","json","text","formData"],A=l._A.Request,E=l._A.Response,T="prototype",_="nr@context";const D={};function N(e){const t=function(e){return(e||n.ee).get("fetch")}(e);if(!(A&&E&&l._A.fetch))return t;if(D[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[_]&&o[_].dt&&(e=o[_].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return D[t.debugId]=1,x.forEach((e=>{r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c<a;c++)s[c]=arguments[c];s[0]=o(s[0],"cb-",i,null,!1),s[1]=o(s[1],"cb-",i,null,!1);const u=n.apply(this,s);return i.nextPromise=u,t.emit("propagate",[e,!0],u,!1,!1),u},a.prototype.then[i]=n,t.on("executor-start",(function(e){e[0]=o(e[0],"resolve-",this,null,!1),e[1]=o(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const B={},F="requestAnimationFrame";function U(e){const t=function(e){return(e||n.ee).get("raf")}(e);if(!l.il||B[t.debugId]++)return t;B[t.debugId]=1;var r=s(t);return r.inPlace(window,[F],"raf-"),t.on("raf-start",(function(e){e[0]=r(e[0],"fn-")})),t}const q={},G="setTimeout",V="setInterval",X="clearTimeout",W="-start",Z="-",$=[G,"setImmediate",V,X,"clearImmediate"];function Q(e){const t=function(e){return(e||n.ee).get("timer")}(e);if(q[t.debugId]++)return t;q[t.debugId]=1;var r=s(t);return r.inPlace(l._A,$.slice(0,2),G+Z),r.inPlace(l._A,$.slice(2,3),V+Z),r.inPlace(l._A,$.slice(3),X+Z),t.on(V+W,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(G+W,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}var Y=r(50);const K={},J=["open","send"];function ee(e){var t=e||n.ee;const r=function(e){return(e||n.ee).get("xhr")}(t);if(K[r.debugId]++)return r;K[r.debugId]=1,v(t);var i=s(r),o=k.Yu.XHR,a=k.Yu.MO,c=k.Yu.PR,u=k.Yu.SI,d="readystatechange",f=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],h=[],g=l._A.XMLHttpRequest.listeners,p=l._A.XMLHttpRequest=function(e){var t=new o(e);function n(){try{r.emit("new-xhr",[t],t),t.addEventListener(d,b,(0,P.m$)(!1))}catch(e){(0,Y.Z)("An error occured while intercepting XHR",e);try{r.emit("internal-error",[e])}catch(e){}}}return this.listeners=g?[...g,n]:[n],this.listeners.forEach((e=>e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e<h.length;e++)m(0,h[e]);h.length&&(h=[])}function E(e,t){return t}return r}},7825:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i<r;i++)n[i]=arguments[i];return function(t){for(var r=arguments.length,n=new Array(r>1?r-1:0),i=1;i<r;i++)n[i-1]=arguments[i];let o=[];return Object.values(e.initializedAgents).forEach((e=>{e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of <".concat(typeof t,"> was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of <".concat(typeof e,"> was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of <".concat(typeof e,"> was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var f=u[d];if(f.getAttribute("src")==r||f.getAttribute("data-webpack")==t+o){s=f;break}}s||(c=!0,(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r),e[r]=[n];var l=(t,n)=>{s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=window.webpackChunkNRBA=window.webpackChunkNRBA||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})();var o={};(()=>{i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i<e.length;i++)t[r=e[i]]=A(this.aggregatedData[r]),t[r].length&&(n=!0),delete this.aggregatedData[r];return n?t:null}}function w(e,t){return null==e?function(e){e?e.c++:e={c:1};return e}(t):t?(t.c||(t=x(t.t)),t.c+=1,t.t+=e,t.sos+=e*e,e>t.max&&(t.max=e),e<t.min&&(t.min=e),t):{t:e}}function x(e){return{t:e,min:e,max:e,sos:e*e,c:1}}function A(e){return"object"!=typeof e?[]:(0,b.D)(e,E)}function E(e,t){return t}var T=i(8632),_=i(4402),D=i(4351);var N=i(7956),O=i(3239),j=i(9251);class S extends h{static featureName=j.t;constructor(e,r){let n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i<n.allowed_origins.length;i++){var o=(0,X.e)(n.allowed_origins[i]);if(e.hostname===o.hostname&&e.protocol===o.protocol&&e.port===o.port){r=!0;break}}return r}isDtEnabled(){var e=(0,t.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.enabled}excludeNewrelicHeader(){var e=(0,t.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,t.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,t.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.cors_use_tracecontext_headers}}var Z=i(7825),$=["load","error","abort","timeout"],Q=$.length,Y=t.Yu.REQ,K=c._A.XMLHttpRequest;class J extends h{static featureName=Z.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<Q;s++)t.addEventListener($[s],this.listener,(0,O.m$)(!1))}function f(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function l(e,t){var r=""+G(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function h(e,t){var r=""+G(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,p.z)()}function m(e,t){t instanceof K&&"load"===e[0]&&n.emit("xhr-load-added",[e[1],e[2]],t)}function v(e,t){t instanceof K&&"load"===e[0]&&n.emit("xhr-load-removed",[e[1],e[2]],t)}function b(e,t,r){t instanceof K&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,p.z)()))}function y(e,t){this.xhrCbStart&&n.emit("xhr-cb-time",[(0,p.z)()-this.xhrCbStart,this.onload,t],t)}function w(e){var t,r=e[1]||{};"string"==typeof e[0]?t=e[0]:e[0]&&e[0].url?t=e[0].url:c._A?.URL&&e[0]&&e[0]instanceof URL&&(t=e[0].href),t&&(this.parsedOrigin=(0,X.e)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=o.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if("string"==typeof e[0]||c._A?.URL&&e[0]&&e[0]instanceof URL){var i={};for(var a in r)i[a]=r[a];i.headers=new Headers(r.headers||{}),s(i.headers,n)&&(this.dt=n),e.length>1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o<Q;o++)t.removeEventListener($[o],this.listener,!1);r.aborted||(n.duration=(0,p.z)()-this.startTime,this.loadCaptureCalled||4!==t.readyState?null==r.status&&(r.status=0):_(this,t),n.cbTime=this.cbTime,i("xhr",[r,n,this.startTime,this.endTime,"xhr"],this,e.D.ajax))}}function T(e,t){var r=(0,X.e)(t),n=e.params;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}function _(e,t){e.params.status=t.status;var r=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?V(e.response):"text"===r||""===r||void 0===r?V(e.responseText):void 0}(t,e.lastSize);if(r&&(e.metrics.rxSize=r),e.sameOrigin){var n=t.getResponseHeader("X-NewRelic-App-Data");n&&(e.params.cat=n.split(", ").pop())}e.loadCaptureCalled=!0}n.on("new-xhr",a),n.on("open-xhr-start",s),n.on("open-xhr-end",u),n.on("send-xhr-start",d),n.on("xhr-cb-time",f),n.on("xhr-load-added",l),n.on("xhr-load-removed",h),n.on("xhr-resolved",g),n.on("addEventListener-end",m),n.on("removeEventListener-end",v),n.on("fn-end",y),n.on("fetch-before-start",w),n.on("fetch-start",x),n.on("fn-start",b),n.on("fetch-done",A)}(r,this.ee,this.handler,this.dt),this.importAggregator())}}var ee=i(3614);const{BST_RESOURCE:te,RESOURCE:re,START:ne,END:ie,FEATURE_NAME:oe,FN_END:ae,FN_START:se,PUSH_STATE:ce}=ee;var ue=i(7836);const{FEATURE_NAME:de,START:fe,END:le,BODY:he,CB_END:ge,JS_TIME:pe,FETCH:me,FN_START:ve,CB_START:be,FN_END:ye}=ue;var we=i(4649);class xe extends h{static featureName=we.t;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})();</script><meta charset="UTF-8"/><meta name="robots" content="index, follow"/><meta name="DC.Creator" content="ShuoHuang"/><meta name="DC.Creator" content="YanWu"/><meta name="DC.Creator" content="ChaoLi"/><meta name="DC.Creator" content="LiXu"/><meta name="DC.Creator" content="JieHuang"/><meta name="DC.Creator" content="YuHuang"/><meta name="DC.Creator" content="WeiweiCheng"/><meta name="DC.Creator" content="BaiXue"/><meta name="DC.Creator" content="LinlinZhang"/><meta name="DC.Creator" content="ShengLiang"/><meta name="DC.Creator" content="XinJin"/><meta name="DC.Creator" content="XinyuanZhu"/><meta name="DC.Creator" content="ShuqiangXiong"/><meta name="DC.Creator" content="YueSu"/><meta name="DC.Creator" content="HuiWang"/><meta name="DC.title" content="Tailoring morphologies of mesoporous polydopamine nanoparticles to deliver high-loading radioiodine for anaplastic thyroid carcinoma imaging and therapy  "/><meta name="DC.publisher" content="Royal Society of Chemistry"/><meta name="DC.Date" content="2021/09/17"/><meta name="DC.Identifier" scheme="doi" content="10.1039/D1NR02892H"/><meta name="DC.Language" content="en"/><meta name="citation_title" content="Tailoring morphologies of mesoporous polydopamine nanoparticles to deliver high-loading radioiodine for anaplastic thyroid carcinoma imaging and therapy  "/><meta name="citation_author" content="ShuoHuang"/><meta name="citation_author" content="YanWu"/><meta name="citation_author" content="ChaoLi"/><meta name="citation_author" content="LiXu"/><meta name="citation_author" content="JieHuang"/><meta name="citation_author" content="YuHuang"/><meta name="citation_author" content="WeiweiCheng"/><meta name="citation_author" content="BaiXue"/><meta name="citation_author" content="LinlinZhang"/><meta name="citation_author" content="ShengLiang"/><meta name="citation_author" content="XinJin"/><meta name="citation_author" content="XinyuanZhu"/><meta name="citation_author" content="ShuqiangXiong"/><meta name="citation_author" content="YueSu"/><meta name="citation_author" content="HuiWang"/><meta name="citation_online_date" content="2021/07/26"/><meta name="citation_date" content="2021"/><meta name="citation_journal_title" content="Nanoscale"/><meta name="citation_volume" content="13"/><meta name="citation_issue" content="35"/><meta name="citation_firstpage" content="15021"/><meta name="citation_lastpage" content="15030"/><meta name="citation_doi" content="10.1039/D1NR02892H"/><meta name="citation_pdf_url" content="https://pubs.rsc.org/en/content/articlepdf/2021/nr/d1nr02892h"/><meta name="citation_abstract_html_url" content="https://pubs.rsc.org/en/content/articlelanding/2021/nr/d1nr02892h"/><meta name="citation_fulltext_html_url" content="https://pubs.rsc.org/en/content/articlehtml/2021/nr/d1nr02892h"/><link rel="shortcut icon" href=""/><link type="text/css" rel="stylesheet" href="/content/stylesheets/rschtml2.css?ver=6_2_1"/><link href="https://www.rsc-cdn.org/oxygen/assets/webfonts/fonts.min.css" rel="stylesheet" type="text/css"/><link type="text/css" rel="stylesheet" href="/content/stylesheets/pubs-ui.min.css"/><meta name="viewport" content="width=device-width, initial-scale=1"/><script type="text/javascript" src="/content/scripts/JQueryPlugins.min.js"></script><script type="text/javascript" src="/content/scripts/GetAnchorText.js"></script><script type="text/javascript">
    
      $(function() {
      $("table.tgroup tfoot th").attr("colspan", "100");
      $("table.tgroup.rtable").each( function (idx, el) {
      var tw = $(this).width();
      $(this).parent().css("min-width", tw+"px");
      });

      });
      
    </script><!--6_2_1--></head><body class="oxy-ui pubs-ui ahtml-page"><!--Google Tag Manager (noscript)--><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-56FZ7G" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><!--End Google Tag Manager (noscript)--><div class="viewport autopad"><div class="pnl pnl--drop autopad"><span id="top"/><div id="wrapper"><div class="left_head"><a class="simple" href="/"><img class="rsc-logo" border="0" src="/content/NewImages/royal-society-of-chemistry-logo.png" alt="Royal Society of Chemistry"/></a><br/><span class="btnContainer"><a class="btn btn--tiny btn--primary" target="_blank" title="Link to PDF version" href="/en/content/articlepdf/2021/nr/d1nr02892h">ViewPDFVersion</a></span><span class="btnContainer"><a class="btn btn--tiny btn--nobg" title="Link to previous article (id:d1nr04001d)" href="/en/content/articlehtml/2021/nr/d1nr04001d" target="_BLANK">PreviousArticle</a></span><span class="btnContainer"><a class="btn btn--tiny btn--nobg" title="Link to next article (id:d1nr03014k)" href="/en/content/articlehtml/2021/nr/d1nr03014k" target="_BLANK">NextArticle</a></span></div><div class="right_head"><div id="crossmark_container"><div id="crossmark-content"><a id="open-crossmark" href="#" data-target="crossmark"><img style="max-width:100px" id="crossmark-logo" src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_square.svg" alt="Check for updates"/></a><script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script></div></div></div><div class="article_info"> DOI:<a target="_blank" title="Link to landing page via DOI" href="https://doi.org/10.1039/D1NR02892H">10.1039/D1NR02892H</a>
(Paper)
<span class="italic"><a title="Link to journal home page" href="https://doi.org/10.1039/2040-3372/2009">Nanoscale</a></span>, 2021, <strong>13</strong>, 15021-15030</div><h1 id="sect220"><span class="title_heading">Tailoring morphologies of mesoporous polydopamine nanoparticles to deliver high-loading radioiodine for anaplastic thyroid carcinoma imaging and therapy<a title="Select to navigate to footnote" href="#fn1"></a></span></h1><p class="header_text">
      <span class="bold">
        
          
            Shuo 
            Huang<a title="Select to navigate to footnote" href="#fn2"></a>
          
        
        
      </span><sup><span class="sup_ref italic">a</span></sup>, 
      <span class="bold">
        
          
            Yan 
            Wu<a title="Select to navigate to footnote" href="#fn2"></a>
          
        
      </span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Chao 
            Li<a title="Select to navigate to footnote" href="#fn2"></a>
          
        
      </span><sup><span class="sup_ref italic">a</span></sup>, 
      <span class="bold">
        
          
            Li 
            Xu
          
        
      </span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Jie 
            Huang
          
        
      </span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Yu 
            Huang
          
        
      </span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Weiwei 
            Cheng
          
        
      </span><sup><span class="sup_ref italic">a</span></sup>, 
      <span class="bold">
        
          
            Bai 
            Xue
          
        
      </span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Linlin 
            Zhang
          
        
      </span><sup><span class="sup_ref italic">a</span></sup>, 
      <span class="bold">
        
          
            Sheng 
            Liang
          
        
      </span><sup><span class="sup_ref italic">a</span></sup>, 
      <span class="bold">
        
          
            Xin 
            Jin
          
        
      </span><span class="orcid"><a target="_blank" title="Select to open ORCID record for XinJin (orcid.org/0000-0003-1779-6407) in a new window" id="connect-orcid-link" href="http://orcid.org/0000-0003-1779-6407"><img id="orcid-id-logo" src="/content/NewImages/orcid_16x16.png" alt="ORCID logo"/></a></span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Xinyuan 
            Zhu
          
        
      </span><span class="orcid"><a target="_blank" title="Select to open ORCID record for XinyuanZhu (orcid.org/0000-0002-2891-837X) in a new window" id="connect-orcid-link" href="http://orcid.org/0000-0002-2891-837X"><img id="orcid-id-logo" src="/content/NewImages/orcid_16x16.png" alt="ORCID logo"/></a></span><sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Shuqiang 
            Xiong
          
        
      </span><span class="orcid"><a target="_blank" title="Select to open ORCID record for ShuqiangXiong (orcid.org/0000-0003-3774-2166) in a new window" id="connect-orcid-link" href="http://orcid.org/0000-0003-3774-2166"><img id="orcid-id-logo" src="/content/NewImages/orcid_16x16.png" alt="ORCID logo"/></a></span>*<sup><span class="sup_ref italic">b</span></sup>, 
      <span class="bold">
        
          
            Yue 
            Su
          
        
      </span><span class="orcid"><a target="_blank" title="Select to open ORCID record for YueSu (orcid.org/0000-0002-6136-6108) in a new window" id="connect-orcid-link" href="http://orcid.org/0000-0002-6136-6108"><img id="orcid-id-logo" src="/content/NewImages/orcid_16x16.png" alt="ORCID logo"/></a></span>*<sup><span class="sup_ref italic">b</span></sup><span class="bold"> and </span>
      <span class="bold">
        
          
            Hui 
            Wang
          
        
      </span><span class="orcid"><a target="_blank" title="Select to open ORCID record for HuiWang (orcid.org/0000-0001-5109-8691) in a new window" id="connect-orcid-link" href="http://orcid.org/0000-0001-5109-8691"><img id="orcid-id-logo" src="/content/NewImages/orcid_16x16.png" alt="ORCID logo"/></a></span>*<sup><span class="sup_ref italic">a</span></sup>
      <br/><a id="affa"><sup><span class="sup_ref italic">a</span></sup></a><span class="italic">Department of Nuclear Medicine, Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School, 1665 Kongjiang Road, Shanghai 200092, China. E-mail: <a href="mailto:wanghui@xinhuamed.com.cn">wanghui@xinhuamed.com.cn</a></span>
      <br/><a id="affb"><sup><span class="sup_ref italic">b</span></sup></a><span class="italic">School of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China. E-mail: <a href="mailto:yuesu@sjtu.edu.cn">yuesu@sjtu.edu.cn</a>; <a href="mailto:xsq123@sjtu.edu.cn">xsq123@sjtu.edu.cn</a></span>
    </p><div id="art-admin"><span class="italic bold">Received 
      6th May 2021
    </span><span class="bold italic">, Accepted 20th July 2021</span></div><p class="bold italic">First published on 26th July 2021</p><hr/><div class="abstract"><h2>Abstract</h2><p>Anaplastic thyroid carcinoma (ATC), as one of the most aggressive human malignancies, cannot be cured by <small><sup>131</sup></small>iodine (<small><sup>131</sup></small>I) internal radiotherapy (RT) because the tumor cells cannot effectively take up <small><sup>131</sup></small>I and are resistant to radiotherapy. In this study, a facile and simple method was proposed to synthesize mesoporous polydopamine nanoparticles (MPDA) and tailor their morphologies by component-adjusting Pluronic micelle-guided polymerization. Then, MPDA were used not only as nanocarriers to radiolabel <small><sup>131</sup></small>I, but also as photothermal conversion agents for photothermal therapy (PTT) to promote RT. The iodine-labeling capacity and photothermal conversion efficiency of MPDA can be enhanced by optimizing their morphologies. It was found that MPDA NPs with a cerebroid pore channel structure (CPDA) showed the highest iodine-carrying capacity and a higher photothermal conversion efficiency as a result of their maximum specific surface area and unique morphology. In subsequent experiments <span class="italic">in vitro</span> and <span class="italic">in vivo</span>, our ATC animal models showed impressive therapeutic responses to CPDA-<small><sup>131</sup></small>I NPs because of the synergistic effect of PTT and RT. Additionally, CPDA-<small><sup>125</sup></small>I NPs can be utilized to obtain high-quality SPETC/CT images of tumors, which can guide clinical therapy for ATC. Considering their great biosafety, these radioiodine-labeled CPDA NPs may serve as a promising tool in combined therapy and diagnosis in ATC.</p></div><hr/>
    
      <h2 id="sect341"><span class="a_heading">Introduction</span></h2>
      <span>Thyroid carcinoma (TC) can be mainly categorized into differentiated thyroid carcinoma (DTC), anaplastic thyroid carcinoma (ATC) and medullary thyroid carcinoma (MTC). Therapy and imaging of metastatic DTC has achieved great success by the way of radiotherapy (RT) of <small><sup>131</sup></small>I, while ATC is still one of the most aggressive malignant solid tumors with a median survival time of only 4 to 12 months, threatening human health seriously.<a title="Select to navigate to reference" href="#cit1"><sup><span class="sup_ref">13</span></sup></a> There has not been an effective treatment strategy for ATC yet.<a title="Select to navigate to reference" href="#cit4"><sup><span class="sup_ref">47</span></sup></a> Therefore, a novel therapeutic regimen is desperately needed. The therapeutic strategy of internal <small><sup>131</sup></small>I RT has the merits of safety, effectiveness and economical treatment modality, but it does not work in the therapy of ATC.<a title="Select to navigate to reference" href="#cit8"><sup><span class="sup_ref">811</span></sup></a> Sodium iodide symporter (NIS) cannot be expressed on the ATC cell membrane, resulting in the failure of intracellular <small><sup>131</sup></small>I enrichment.<a title="Select to navigate to reference" href="#cit12"><sup><span class="sup_ref">1214</span></sup></a> Therefore, effectively delivering <small><sup>131</sup></small>I to the tumor site is a hopeful way for ATC treatment.</span>
      <p class="otherpara">With the development of nanomedicine over the past few decades, it has been demonstrated that nanoparticles as nanocarriers have successfully realized the delivery of <small><sup>131</sup></small>I to target tumors.<a title="Select to navigate to reference" href="#cit15"><sup><span class="sup_ref">1518</span></sup></a> Nevertheless, this kind of treatment still has its limitations to ATC patients, including low <small><sup>131</sup></small>I loading capacity of nanocarriers and radiotherapy resistance. Nowadays, porous nanoparticles show huge advantages in the field of drug delivery, which can effectively improve the loadings of chemotherapeutic drugs<a title="Select to navigate to reference" href="#cit19"><sup><span class="sup_ref">19,20</span></sup></a> or other substances.<a title="Select to navigate to reference" href="#cit21"><sup><span class="sup_ref">21,22</span></sup></a> A good case in point is that mesoporous silicon dioxide nanoparticles (MPSNs) were used as nanocarriers for loading various drug molecules by their open pore structure and adjustable pore channels to treat cancer.<a title="Select to navigate to references" href="#cit19"><sup><span class="sup_ref">19</span></sup></a> However, improving <small><sup>131</sup></small>I loading capacity by constructing mesoporous nanoparticles has not yet been achieved because their surfaces lack effective functional groups to anchor <small><sup>131</sup></small>I. More importantly, due to the failure of monotherapy, the combination of two or more treatments is recommended in ATC patients.<a title="Select to navigate to reference" href="#cit23"><sup><span class="sup_ref">2325</span></sup></a> Adding hyperthermia to radiotherapy prevents DNA breaks from getting repaired, resulting in more residual DNA breaks and cell apoptosis.<a title="Select to navigate to reference" href="#cit26"><sup><span class="sup_ref">2628</span></sup></a> Thanks to the tunability of the nanostructure and the components of nanoparticles, different therapeutic strategies and imaging modalities can be combined in one nanoparticle system to synergistically treat the tumors.<a title="Select to navigate to reference" href="#cit29"><sup><span class="sup_ref">29,30</span></sup></a> Therefore, designing and synthesizing porous nanoparticles with high <small><sup>131</sup></small>I loading for radiotherapy, combined with hyperthermia, is most likely a great breakthrough in the treatment of ATC.</p>
      <p class="otherpara">Polydopamine (PDA), as a biocompatible molecule, has attracted tremendous attention in biomedicine.<a title="Select to navigate to reference" href="#cit31"><sup><span class="sup_ref">3134</span></sup></a> PDA and its coated nanoparticles have been widely used as near-infrared (NIR) light-absorbing agents for photothermal therapy (PTT) because PDA materials can strongly absorb light in the region of NIR (wavelength, 7001100 nm).<a title="Select to navigate to reference" href="#cit35"><sup><span class="sup_ref">3537</span></sup></a> NIR-induced PTT is a minimally invasive therapeutic approach that converts light energy into heat to ablate tumors.<a title="Select to navigate to reference" href="#cit38"><sup><span class="sup_ref">3841</span></sup></a> Moreover, the abundant active groups such as OH and NH<small><sub>2</sub></small> on the surface of the PDA materials can be conjugated by various therapeutic molecules for RT and chemotherapy.<a title="Select to navigate to reference" href="#cit42"><sup><span class="sup_ref">42,43</span></sup></a> PDA nanomaterials show excellent NIR-absorbing capability due to the existence of a benzoquinone structure.<a title="Select to navigate to references" href="#cit42"><sup><span class="sup_ref">42</span></sup></a> In addition, PDA containing phenolic hydroxyl group is beneficial for the conjugation of <small><sup>131</sup></small>I for RT. Therefore, PDA nanocarriers combined with RT and PTT were developed to improve the therapeutic effect of ATC.</p>
      <p class="otherpara">Multiform PDA nanocarriers were firstly synthesized by Pluronic micelle-guided polymerization assembly in alkaline solution. Then, <small><sup>131</sup></small>I was labeled to the surface of the PDA nanocarrier by the iodogen method.<a title="Select to navigate to references" href="#cit44"><sup><span class="sup_ref">44</span></sup></a> The morphological features and physicochemical properties of PDA nanocarriers were investigated through SEM, TEM and BET. The photothermal conversion efficiency, <small><sup>131</sup></small>I-labeling rate and cellular uptake rate of various PDA nanoparticles were compared <span class="italic">in vitro</span>. The antitumor activity of <small><sup>131</sup></small>I-radiolabeled cerebroid polydopamine nanoparticles (CPDA-<small><sup>131</sup></small>I) was evaluated <span class="italic">in vitro</span> and <span class="italic">in vivo</span>. Furthermore, SPECT/CT was used to perform <span class="italic">in vivo</span> imaging and characterize the biodistribution of the nanoparticles. Finally, histopathology was used to evaluate the biosafety of CPDA-<small><sup>131</sup></small>I. In this work, the morphology of PDA nanoparticles can be precisely controlled by changing the composition of micelles. Moreover, the desirable porous structure and specific surface area can be obtained by the optimization of the morphology to enhance the loading of <small><sup>131</sup></small>I for RT and photothermal conversion efficiency for PTT. Our study demonstrates that CPDA can significantly improve <small><sup>131</sup></small>I delivery capacity and photothermal conversion efficiency, which provides a new approach for ATC therapy by combining PTT and RT together (<a title="Select to navigate to scheme" href="#imgsch1">Scheme 1</a>).</p>
      <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgsch1"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-s1_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-s1.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-s1.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Scheme 1 </b> <span id="sch1"><span class="graphic_title">Schematic illustration of the synthesis procedure of CPDA-<small><sup>125</sup></small>/<small><sup>131</sup></small>I for SPCECT/CT guided combined therapy of RT and PTT <span class="italic">in vivo</span>.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
    
    
      <h2 id="sect392"><span class="a_heading">Experimental</span></h2>
      
        <h3 id="sect394"><span class="b_heading">Materials</span></h3>
        <span>Dopamine hydrochloride (DA) was purchased from J&amp;K Chemical Co. Ltd. Pluronic F127 and P123, sodium hydroxide (NaOH), methylene dichloride, sodium iodide, calcein-acetoxymethyl (calcein-AM) and propidium iodide (PI), and iodogen were obtained from Sigma-Aldrich Co. Ltd. Anhydrous ethanol (EOH) and ammonium hydroxide (2628%) were provided by Sinopharm Chemical Reagent Co. Ltd. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), trypsinEDTA, Alexa Fluor 488 annexin V and MEM nonessential amino acids (NEAA) were supplied by Thermo Fisher Scientific Co. Ltd. Cell counting kit-8 (CCK-8) was purchased from Shanghai Yuanzhi Biotechnology Co. Ltd. <small><sup>131</sup></small>I was purchased from Shanghai Xinke Co. Ltd. Deionized water was used for all experiments and all chemical reagents were used as received without further purification.</span>
      
      
        <h3 id="sect398"><span class="b_heading">Synthesis of PDA nanoparticles with different morphologies</span></h3>
        <span>The multiform PDA nanoparticles weresynthesized by mixing different feed ratio of F127 and P123 guided polymerization assembly. In brief, 0.5 g of F127 and P123 with different ratios of 1<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>0, 3<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>1, 1<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>1, 1<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>3 and 0<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>1 was dispersed in deionized water for 0.5 h to form a uniform solution. Then, DA (0.2 g) was added to the above solution. After that, 0.5 mL of ammonium hydroxide was dropped into the reaction mixture to trigger the polymerization of DA. The whole reaction process lasted for 24 h at the temperature of 90 C under gentle stirring. Finally, the resultant PDA nanoparticles were collected by centrifugation and then washed with water and ethanol several times to remove the template of the micelles. SPDA was prepared according to a previously reported method without templates.<a title="Select to navigate to references" href="#cit45"><sup><span class="sup_ref">45</span></sup></a></span>
      
      
        <h3 id="sect402"><span class="b_heading">Characterization</span></h3>
        <span>Transmission electron microscopy (TEM, Tecnai G2 Spirit Biotwin, USA) and scanning electron microscopy (SEM, JEOL JSM-7800F Prime, USA) were carried out to observe the morphologies of these PDA nanoparticles. The hydrodynamic diameter and zeta potential of these nanoparticles were detected using a Zetasizer Nanoseries ZS (Malvern, UK). The N<small><sub>2</sub></small> adsorption/desorption isotherms were recorded using a SSA and porosity analyzer (Autosorb-IQ3, USA) at 196 C. All these samples were degassed in a vacuum at 140 C overnight before the measurements, and then the SSA and pore size distributions of the nanoparticles were calculated based on the BrunauerEmmettTeller (BET) and BarrettJoynerHalenda (BJH) methods, respectively. UV-vis-NIR absorption spectrum of the CPDA solution (0.01 mg mL<small><sup>1</sup></small>) was scanned and recorded from 200 nm to 1100 nm.</span>
      
      
        <h3 id="sect407"><span class="b_heading">
          <small><sup>131</sup></small>I labeling, radiolabeling stability and cellular uptake assay</span></h3>
        <span>To compare the iodine-labeling capacity of the PDA nanoparticles with different morphologies, these PDA nanoparticles were labeled with <small><sup>131</sup></small>I by the approach of the iodogen method. The reaction processes were performed under the same procedures. Briefly, 10 l of Na<small><sup>131</sup></small>I (50 mCi mL<small><sup>1</sup></small>) and 50 L of PDA nanoparticles (5 mg mL<small><sup>1</sup></small>) were dropped into 1.5 mL Eppendorf (EP) tubes that were pre-coated with iodogen. The reaction mixtures were shaken at 1000 rpm for 10 min at 37 C. The <small><sup>131</sup></small>I-labeling rates (RLR) were determined by radioactive thin-layer chromatography (Radio-TLC, Germany) using NaCl solutions (0.9%) as the mobile phase according to <a title="" href="#eqn1">eqn (1)</a>. <span class="italic">P</span><small><sub>t</sub></small> and <span class="italic">C</span><small><sub>a</sub></small> are the sums of the counts measured of the target peaks and all chromatograms, respectively.<table><td class="leftEqn"></td><tr><td class="eqn"><span id="eqn1"/><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-t1_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-t1.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-t1.gif"/></a></td><td class="rightEqn">(1)</td></tr></table></span>
        <p class="otherpara">Excess <small><sup>131</sup></small>I was removed by centrifugation filtration with the 10 kDa molecular weight cut-off (MWCO) membrane before the <span class="italic">in vitro</span> and <span class="italic">in vivo</span> experiments. To investigate the cellular uptake of these PDA-<small><sup>131</sup></small>I nanoparticles, 8305C cells were seeded in 24-well plates at a density of 5  10<small><sup>5</sup></small> cells per well and incubated overnight for attachment. Next, these PDA-<small><sup>131</sup></small>I nanoparticles (5 Ci) or free <small><sup>131</sup></small>I (5 Ci) were added into the above wells and allowed to incubate for 1 h. The cells were washed with precooled PBS three times, and the PBS was collected for further measurement. Then, the cells were lysed by NaOHSDS solutions (0.2 M NaOH, 1% sodium dodecyl sulfate, SDS). The radioactivity of both cell lysates and PBS was detected using a gamma counter (SN-695, Solar Ring Photoelectric Instrument, Shanghai). Furthermore, the radiolabeling stability of CPDA-<small><sup>131</sup></small>I was examined in PBS (1 mM, pH 7.4) and fetal bovine serum at 37 C, and the RLR of CPDA-<small><sup>131</sup></small>I in the two solutions at 0 h, 6 h, 12 h, 1 d, 3 d, 5 d and 7d was detected using TLC and the gamma counter.</p>
      
      
        <h3 id="sect434"><span class="b_heading">
          <span class="italic">In vitro</span> photothermal conversion performance</span></h3>
        <span>To evaluate the photothermal conversion efficiency of the CPDA nanoparticles <span class="italic">in vitro</span>, SPDA and CPDA (1 mL, 400 g mL<small><sup>1</sup></small>) were irradiated using an 808 nm laser at a power of 1 W cm<small><sup>2</sup></small> for 5 min. During the irradiation, a thermal infrared camera (Fluke Ti110, USA) was used to take real-time thermal images and record the temperature changes of the solutions. Furthermore, the thermal stability of the PDA nanoparticles was also investigated. After the same laser irradiation, all the solutions were allowed to cool down in 10 minutes and this process was repeated 5 times and the temperature was recorded in real time using the thermal infrared camera. The photothermal conversion efficiency (<span class="italic"></span>) and time constant (<span class="italic"></span><small><sub>s</sub></small>) were calculated using two previously reported equations, which are shown as <a title="" href="#eqn2">eqn (2) and (3)</a>, respectively.<a title="Select to navigate to reference" href="#cit46"><sup><span class="sup_ref">4648</span></sup></a><table><td class="leftEqn"></td><tr><td class="eqn"><span id="eqn2"/><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-t2_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-t2.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-t2.gif"/></a></td><td class="rightEqn">(2)</td></tr></table><table><td class="leftEqn"></td><tr><td class="eqn"><span id="eqn3"/><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-t3_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-t3.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-t3.gif"/></a></td><td class="rightEqn">(3)</td></tr></table></span>
        <p class="otherpara">
          <span class="italic">h</span> and <span class="italic">S</span> are the heat transfer coefficient and the SSA of photothermal agents, respectively. <span class="italic">T</span><small><sub>max</sub></small> and <span class="italic">T</span><small><sub>out</sub></small> refer to the equilibrium temperature of the solutions and the ambient temperature, respectively. <span class="italic">Q</span><small><sub>dis</sub></small> represents the heat dissipation associated with the light absorbance of the solution in the container alone. <span class="italic">I</span> and <span class="italic">A</span><small><sub>808</sub></small> are the power intensity and the absorbance of photothermal agents at 808 nm, respectively. <span class="italic">m</span><small><sub>s</sub></small> and <span class="italic">C</span><small><sub>s</sub></small> stand for the mass and the heat capacity of aqueous solution, respectively.</p>
      
      
        <h3 id="sect468"><span class="b_heading">Cell culture</span></h3>
        <span>The L929, a mouse fibroblast cell line, was originally provided by the American Type Culture Collection (ATCC, USA). 8305C, a human anaplastic thyroid carcinoma cell line, was obtained from Zhong Qiao Xin Zhou Biotechnology Co. Ltd (Shanghai, China). L929 cells were cultured in DMEM containing 10% FBS, while 8305C cells were cultured in DMEM supplemented with 10% FBS, 1% GlutaMAX and 1% NEAA (100) under a humidified atmosphere containing 5% CO<small><sub>2</sub></small> at 37 C.</span>
      
      
        <h3 id="sect472"><span class="b_heading">
          <span class="italic">In vitro</span> cytotoxicity assay</span></h3>
        <span>For the <span class="italic">in vitro</span> cytotoxicity assay, L929 cells at the logarithmic growth phase were seeded into 96-well plates at 5  10<small><sup>3</sup></small> cells per well and cultured for 22 h for attachment. The cells were exposed to different concentrations of CPDA and further co-cultured for 24 h. Then 10 L of CCK-8 reagent was added into each well, and the absorbance value of each sample well at 450 nm was detected using a microplate reader (Varioskan Flash, Thermo Scientific).</span>
        <p class="otherpara">To investigate <span class="italic">in vitro</span> PTT and radiotherapy effects of CPDA-<small><sup>131</sup></small>I, 8305C cells were seeded in 96-well plates at a density of 6  10<small><sup>3</sup></small> cells per well and incubated for 22 h for cell attachment. Then, the 8305C cells were treated with various concentrations of CPDA with or without <small><sup>131</sup></small>I and an 808 nm laser at 1 W cm<small><sup>2</sup></small> for 5 min. 24 h later, the cell viabilities relative to the control cells were determined using a standard CCK-8 assay. In order to understand the detailed synergistic interaction between the PTT of CPDA + NIR and radiotherapy of <small><sup>131</sup></small>I, the combination index (CI) was calculated using an equation reported previously <a title="" href="#eqn4">eqn (4)</a>.<a title="Select to navigate to reference" href="#cit49"><sup><span class="sup_ref">49,50</span></sup></a><table><td class="leftEqn"></td><tr><td class="eqn"><span id="eqn4"/><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-t4_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-t4.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-t4.gif"/></a></td><td class="rightEqn">(4)</td></tr></table></p>
        <p class="otherpara">In this equation, <span class="italic">D</span><small><sub>1</sub></small> and <span class="italic">D</span><small><sub>2</sub></small> are the doses of drug 1 and drug 2, which can produce a particular Fa (<span class="italic">e.g.</span>, 75% inhibition of cell viability), and <span class="italic">D</span><small><sub><span class="italic">x</span>1</sub></small> and <span class="italic">D</span><small><sub><span class="italic">x</span>2</sub></small> are the doses of drugs achieving the same Fa. CI value greater than 1.1 indicates an antagonistic effect, CI value between 0.9 and 1.1 manifests an additive effect, and CI value less than 0.9 manifests a synergistic effect.</p>
        <p class="otherpara">As for the calcein AM/PI co-stained study, 8305C cells were cultured in a 12-well plate at a density of 2  10<small><sup>5</sup></small> per well and treated with PBS, PBS + NIR, CPDA-<small><sup>131</sup></small>I, CPDA + NIR and CPDA-<small><sup>131</sup></small>I + NIR (CPDA with or without <small><sup>131</sup></small>I: 100 g mL<small><sup>1</sup></small>; NIR: 808 nm, 1 W cm<small><sup>2</sup></small>, 5 min; <small><sup>131</sup></small>I: 160 Ci mL<small><sup>1</sup></small>). 4 h later, the 8305C cells were co-stained using calcein-AM/PI and observed under a fluorescence microscope (Leica, TCS SP8, Germany). Flow cytometry assay was adopted to investigate the apoptosis of 8305C cells. The cells were treated in the same manner as in the calcein AM/PI co-stained study and were stained using an Alexa Fluor 488 annexin V kit. Then, the cells were collected and analyzed using a BD LSRFortessa flow cytometer. To evaluate the DNA damage levels of the 8305C cells after various treatments (CPDA with or without <small><sup>131</sup></small>I: 100 g mL<small><sup>1</sup></small>; NIR: 808 nm, 1 W cm<small><sup>2</sup></small>, 5 min; <small><sup>131</sup></small>I: 160 Ci mL<small><sup>1</sup></small>), -H2AX immunofluorescence staining assay was performed. The 8305C cells were seeded in a 24-well confocal plate at a density of 5  10<small><sup>4</sup></small> cells per well and incubated overnight, followed by various treatments (CPDA with or without <small><sup>131</sup></small>I: 100 g mL<small><sup>1</sup></small>; NIR: 808 nm, 1 W cm<small><sup>2</sup></small>, 5 min; <small><sup>131</sup></small>I: 160 Ci mL<small><sup>1</sup></small>). Then, 4% paraformaldehyde and Triton X-100 were used to fix the cells and permeate the cells. 5% bovine serum albumin was added to block the nonspecific reaction sites. Next, primary antibodies (-H2AX and ab81299; Abcam Inc.) and their corresponding secondary antibodies with a CY3 tag were incubated with the cells in the dark. DAPI was used to stain the cell nuclei and then the cells were washed with PBS 3 times. Finally, fluorescence images were acquired by using confocal fluorescence microscopy (Olympus, IX73, Japan).</p>
      
      
        <h3 id="sect522"><span class="b_heading">Animals and tumor models</span></h3>
        <span>BALB/c mice (4 weeks) and Sprague-Dawley (SD) rats (200 g) were purchased from Shanghai Lingchang Company. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of Shanghai Jiao Tong University and approved by the Animal Ethics Committee of Xin Hua Hospital affiliated to the Shanghai Jiao Tong University School of Medicine (Shanghai, China). The 8305C (2  10<small><sup>6</sup></small>) cells were suspended in 200 L of DMEM (containing 50% Matrigel, 356234, Corning) and then they were injected subcutaneously into the right armpit of each mouse.</span>
      
      
        <h3 id="sect526"><span class="b_heading">
          <span class="italic">In vivo</span> photothermal performance</span></h3>
        <span>When the tumors grew up to 10001500 mm<small><sup>3</sup></small>, the 8305C tumor-bearing nude mice were randomly divided into two groups (<span class="italic">n</span> = 3). One group was administered with 200 l of PBS <span class="italic">via</span> the tail vein, and the other group was injected with 200 l of CPDA (1 mg mL<small><sup>1</sup></small>). After 6 h, all tumors were exposed to an 808 nm laser at 1 W cm<small><sup>2</sup></small> for 5 min and real-time thermal images were recorded at predetermined time point time points using an infrared camera.</span>
      
      
        <h3 id="sect535"><span class="b_heading">
          <span class="italic">In vivo</span> SPECT/CT imaging</span></h3>
        <span>
          <small><sup>125</sup></small>I is a type of radionuclide with a low-energy gamma ray and a long half-life (60 days) and is more suitable to obtain high quality SPECT/CT images and to monitor the metabolism of long-circulating drugs in the body compared to <small><sup>131</sup></small>I. Therefore, in this study, <small><sup>125</sup></small>I was used to perform <span class="italic">in vivo</span> SPECT/CT imaging. 8305C tumor-bearing mice were injected with 200 L CPDA-<small><sup>125</sup></small>I (200 Ci) through their tail vein and images were obtained using a SPECT/CT system (MI Lab, the Netherlands) at various time points (1 h, 24 h, 3 d and 7 d). PMOD software (PMOD Technologies LLC, USA) was used to analyze the SPECT/CT images.</span>
      
      
        <h3 id="sect544"><span class="b_heading">Blood circulation and biodistribution</span></h3>
        <span>To evaluate the blood circulation of CPDA-<small><sup>131</sup></small>I, blood of SD rats was collected from the retinal vein of mice (<span class="italic">n</span> = 3) at various time points (10 min, 30 min, 1 h, 2 h, 6 h, 12 h, 24 h and 48 h) after intravenous injection of CPDA-<small><sup>131</sup></small>I (1 mL, 0.4 mCi). To quantitatively analyze the biodistribution of CPDA-<small><sup>131</sup></small>I in different organs, nude mice (<span class="italic">n</span> = 3) were sacrificed by neck dissection 24 h after intravenous injection. The heart, liver, spleen, lungs, kidneys, muscle, skin, bone, brain and tumor were collected and weighed. The radioactivity of the blood samples and the major organs were determined using a gamma counter.</span>
      
      
        <h3 id="sect552"><span class="b_heading">
          <span class="italic">In vivo</span> tumor radiotherapy and photothermal therapy</span></h3>
        <span>The 8305C tumor-bearing mice were divided randomly into 5 groups (<span class="italic">n</span> = 5) when the tumor volume reached approximately 100 mm<small><sup>3</sup></small>. Then, the 5 groups were treated with various formulations, including 200 L PBS with or without NIR irradiation (808 nm, 1 W cm<small><sup>2</sup></small>, 5 min), CPDA (200 L, 1 mg L<small><sup>1</sup></small>) with NIR irradiation, and CPDA-<small><sup>131</sup></small>I (200 L, 1 mg mL<small><sup>1</sup></small> of CPDA, 400 Ci of <small><sup>131</sup></small>I) with or without NIR irradiation. In the two RT groups, CPDA-<small><sup>131</sup></small>I was injected intravenously every 6 days. Furthermore, the three groups with NIR irradiation were injected with CPDA or PBS solution every 2 d, and then the tumor sites were irradiated using a NIR laser for 6 h after the injection. The tumor volumes and body weights of all groups were monitored during the therapy period and the tumor volumes were calculated using the following equation (<a title="" href="#eqn5">eqn (5)</a>).<table><td class="leftEqn"></td><tr><td class="eqn"><span id="eqn5"/><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-t5_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-t5.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-t5.gif"/></a></td><td class="rightEqn">(5)</td></tr></table></span>
        <p class="otherpara">The relative body weight, relative tumor volume and relative tumor weight were calculated as <span class="italic">W</span>/<span class="italic">W</span><small><sub>0</sub></small>, <span class="italic">V</span>/<span class="italic">V</span><small><sub>0</sub></small> and <span class="italic">V</span>/<span class="italic">V</span><small><sub>PBS</sub></small>, respectively. All mice were sacrificed by neck dissection after 22 days. The tumor tissues were collected and immersed in 4% paraformaldehyde for 24 h, followed by hematoxylin and eosin (H&amp;E) staining and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) immunofluorescence staining assay. The major organs, including the heart, liver, spleen, lungs and kidneys of each group, were harvested for further H&amp;E staining.</p>
      
      
        <h3 id="sect578"><span class="b_heading">Statistical analysis</span></h3>
        <span>All data were presented as mean  stand deviation (S.D.). Student's <span class="italic">t</span>-test was used to compare the differences among groups and <span class="italic">p</span> &lt; 0.05 was considered to be statistically significant.</span>
      
    
    
      <h2 id="sect583"><span class="a_heading">Results and discussion</span></h2>
      
        <h3 id="sect585"><span class="b_heading">Characterization</span></h3>
        <span>As illustrated in <a title="Select to navigate to scheme" href="#imgsch2">Scheme 2</a>, mesoporous polydopamine nanoparticles can be easily synthesized under Pluronic micelle guided polymerization assembly by changing the ratio of F127 and P123, which were used to adjust the morphologies of PDA nanoparticles. The SEM and TEM images (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1a</a> and Fig. S1a<a title="Select to navigate to footnote" href="#fn1"></a>) found that DA was self-assembled into smooth polydopamine nanoparticles (SPDA) in the absence of micelles. However, the morphologies of the PDA nanoparticles dramatically changed when adding F127 or P123 into the reaction system. By simply adjusting the F127/P123 ratio from 1<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>0 to 3<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>1, 1<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>1 and 1<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>3, and then to 0<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>:<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/>1, the morphology of the PDA nanoparticles can be continuously tuned from polyporous polydopamine nanoparticles (PPDA) to macroporous polydopamine nanoparticles (MPDA), cerebroid polydopamine nanoparticles (CPDA), bowl-shaped polydopamine nanoparticles (BPDA) and acetabuliform polydopamine nanoparticles (APDA), respectively (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1bf</a> and Fig. S1bf<a title="Select to navigate to footnote" href="#fn1"></a>). The morphological features of PDA nanoparticles depended on the composition of Pluronic micelles, so we proposed a versatile template oriented assembly process for these PDA nanoparticles with various morphologies (<a title="Select to navigate to scheme" href="#imgsch2">Scheme 2</a>). Pluronic polymer (polyoxyethylenepolyoxypropylenepolyoxyethylene, abbreviated as PEOPPOPEO) is a type of thermosensitive triblock copolymer composed of hydrophobic and hydrophilic chain segments, facilitating an adjustable shape formation of Pluronic micelles by changing the ratio of P123/F127. Therefore, we were able to adopt Pluronic micelles with different ratios of F127 and P123 to guide the polymerization of dopamine to obtain various morphologies of MPDA nanoparticles. With the increasing content of P123, the size of spherical micelles increases from 5 nm to 30 nm, as verified by the corresponding mesoporous size of PDA nanoparticles (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1b and c</a>). When the proportion of P123 increased to 50%, the shape of Pluronic micelles transformed from nanosphere to one-dimensional nanorods, resulting in the formation of CPDA. Interestingly, further increasing the percentage of P123 generated two-dimensional Pluronic micelles, BPDA and APDA. In a word, the morphologies of PDA nanoparticles can be adjusted by the ratio of Pluronic micelles. The as-prepared PDA nanoparticles exhibited a uniform size distribution range from 100 to 200 nm, except for agglomerated APDA and BPDA due to their flat morphology. Furthermore, the hydrodynamic diameter and zeta potential of the as-synthesized PDA nanoparticles were determined using a Nano Sizer. The average hydrodynamic diameters of the six different PDA nanoparticles were distributed between 176.3  4.5 nm and 205.7  9.2 nm, which were larger than the diameters in the SEM or TEM images due to the hydration environment.<a title="Select to navigate to reference" href="#cit51"><sup><span class="sup_ref">5154</span></sup></a> And the polydispersity index (PDI) of these PDA nanoparticles only ranged from 0.142  0.018 to 0.268  0.015, manifesting the uniformity of these PDA nanoparticles (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1g</a>). Zeta potential was measured to evaluate the stability of the PDA nanoparticle dispersions. As shown in <a title="Select to navigate to figure" href="#imgfig1">Fig. 1h</a>, the zeta potentials of the six different PDA nanoparticles were between 32.8 and 26.3 mV, suggesting their high ionization and good dispersion in water. Moreover, the specific surface area (SSA) and pore size were calculated by the BrunauerEmmettTeller (BET) and BarrettJoynerHalenda (BJH) methods, respectively.<a title="Select to navigate to reference" href="#cit55"><sup><span class="sup_ref">5557</span></sup></a> As shown in <a title="Select to navigate to figure" href="#imgfig1">Fig. 1i</a> and Fig. S2,<a title="Select to navigate to footnote" href="#fn1"></a> compared with the SPDA, the other five PDA nanoparticles displayed significant increases in the SSA because of their porous characteristics. Among them, CPDA showed the highest SSA of 57.1  6.4 m<small><sup>2</sup></small> g<small><sup>1</sup></small>, which is almost 13 times higher than that of the SPDA (4.5  0.7 m<small><sup>2</sup></small> g<small><sup>1</sup></small>). These nanoparticles also showed a flexible pore size from 5 nm to 31.8 nm, consistent with the results from the SEM and TEM images. The surface composition of the PDA nanoparticles, and the FT-IR and XPS spectra are shown in Fig. S3.<a title="Select to navigate to footnote" href="#fn1"></a></span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgsch2"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-s2_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-s2.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-s2.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Scheme 2 </b> <span id="sch2"><span class="graphic_title">Schematic illustration of the synthesis and mechanism of the PDA nanoparticles with various morphologies: smooth polydopamine nanoparticles (SPDA), polyporous polydopamine nanoparticles (PPDA), macroporous polydopamine nanoparticles (MPDA), cerebroid polydopamine nanoparticles (CPDA), bowl-shaped polydopamine nanoparticles (BPDA), acetabuliform polydopamine nanoparticles (APDA).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig1"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-f1_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-f1.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-f1.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 1 </b> <span id="fig1"><span class="graphic_title">SEM images of (af) SPDA, PPDA, MPDA, CPDA, BPDA and APDA. (g) Hydrodynamic sizes (<span class="italic">n</span> = 3), polydispersity index (PDI) and (h) zeta potential of various PDA nanoparticles (<span class="italic">n</span> = 3). (i) Specific surface area (<span class="italic">n</span> = 3) and (j) <small><sup>131</sup></small>I labeling rate of various PDA nanoparticles (<span class="italic">n</span> = 3). (k) Cell uptake of various PDA-<small><sup>131</sup></small>I nanoparticles and free <small><sup>131</sup></small>I (<span class="italic">n</span> = 3). (l) <small><sup>131</sup></small>I labeled stability of various PDA in PBS (1 mM, pH 7.4) or fetal bovine serum at 37 C.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      
      
        <h3 id="sect619"><span class="b_heading">Radioiodine-labeling assay</span></h3>
        <span>To compare the <small><sup>131</sup></small>I-labeling capacity of various PDA nanoparticles, the iodine-labeling reaction was carried out using the iodogen method. As revealed in <a title="Select to navigate to figure" href="#imgfig1">Fig. 1j</a>, the highest SSA of CPDA exhibited the highest iodine-labeling rate (88.39%  5.17), while the lowest iodine-labeling rate (16.14%  4.90) was found in PPDA in spite of its second largest SSA. In contrast, SPDA ranked second in the iodine-labeling rate, however it had the lowest SSA. Taking these results into consideration, we inferred the highest iodine-labeling rate of CPDA may be attributed to their large SSA and cerebriform shape. To be more specific, the ravine structure of CPDA not only provided high active sites (phenolic hydroxyl groups) to conjugate iodine, but also did not impede hydrophobic iodine to substitute the hydrogen proton by the electrophilic substitution reaction. However, the small pores of PPDA were not beneficial for the occurrence of the labeling reaction. Moreover, the iodine-labeling rates of the APDA and BPDA were only 48.16%  5.27 and 41.73%  6.3, respectively. We thought their aggregation-prone characteristic was an obstacle to the labeling reaction. To quantify their cellular uptake capability, all of the PDA-<small><sup>131</sup></small>I nanoparticles were separately incubated with ATC cell line 8305C cells for 1 h (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1k</a>). All PDA-<small><sup>131</sup></small>I nanoparticles showed a higher cellular uptake rate than free <small><sup>131</sup></small>I, mainly attributed to the uptake path of nanoparticles. Among these nanoparticles, CPDA-<small><sup>131</sup></small>I exhibited the highest cellular uptake rate (8.90%  0.89), which is approximately 130 times higher than that of free <small><sup>131</sup></small>I (0.07%  0.00). As expected, the lowest iodine-labeling rate of PPDA-<small><sup>131</sup></small>I showed approximately one-tenth cellular uptake rate of CPDA-<small><sup>131</sup></small>I (0.94%  0.29). These results demonstrated that the cellular uptake rate of PDA-<small><sup>131</sup></small>I nanoparticles is associated with their iodine-labeling capacity and morphology. Therefore, we believe that the iodine-labeling capacity of nanoparticles can be optimized by morphology control and can thus improve the <small><sup>131</sup></small>I delivery efficiency to 8305C cells. In addition, CPDA-<small><sup>131</sup></small>I exhibited great radiolabeling stability in PBS and serum after incubation for 7 d (<a title="Select to navigate to figure" href="#imgfig1">Fig. 1l</a>).</span>
      
      
        <h3 id="sect636"><span class="b_heading">
          <span class="italic">In vitro</span> and <span class="italic">in vivo</span> photothermal performance</span></h3>
        <span>In order to perform photohyperthermia combined with radiotherapy for ATC, the material should have high photothermal conversion capacity. Therefore, the photothermal conversion experiment for CPDA and SPDA by recording the temperature of deionized water was carried out. As shown in <a title="Select to navigate to figure" href="#imgfig2">Fig. 2a</a>, the temperature increased with increasing irradiation time. Under irradiation of an 808 nm laser at a density of 1 W cm<small><sup>2</sup></small> for 5 min, the maximum temperatures of CPDA and SPDA could reach 59.7 C and 50.3 C, respectively (<a title="Select to navigate to figure" href="#imgfig2">Fig. 2b</a>). Specifically, the temperature change (<span class="italic">T</span>) of CPDA was 32.5 C, 9.3 C higher than SPDA, as calculated and shown in <a title="Select to navigate to figure" href="#imgfig2">Fig. 2c</a>. These results suggested that the photothermal conversion efficiency of PDA is greatly improved by changing the morphology and increasing SSA. After turning off the laser, temperatures of the three PDA nanoparticles slowly cooled down to room temperature in 10 min (<a title="Select to navigate to figure" href="#imgfig2">Fig. 2c</a>). Furthermore, no significant degradation of temperature curves was observed among these PDA nanoparticles throughout five irradiation cycles (<a title="Select to navigate to figure" href="#imgfig2">Fig. 2d</a>). By plotting the cooling time <span class="italic">versus</span> ln<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/><span class="italic"></span>, the time constant <span class="italic"></span><small><sub>s</sub></small> of CPDA and SPDA for photothermal conversion was determined to be 225.9 s and 256.5 s, respectively, based on the linear regression analysis (<a title="Select to navigate to figure" href="#imgfig2">Fig. 2e</a>). According to the formulas previously reported, the photothermal conversion efficiency (<span class="italic"></span>) of CPDA was calculated to be 50.3%, which is higher than that of SPDA (41.6%). These data demonstrated that CPDA not only has excellent photothermal conversion ability, but also has robust photothermal stability.</span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig2"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-f2_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-f2.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-f2.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 2 </b> <span id="fig2"><span class="graphic_title">(a) Thermal images of CPDA and SPDA (400 g mL<small><sup>1</sup></small>) under laser irradiation. (b) Real-time temperature of CPDA and SPDA under the irradiation of an 808 nm laser at a density of 1 W cm<small><sup>2</sup></small> for 5 min. (c) Temperature changes (<span class="italic">T</span>) of CPDA and SPDA (400 g mL<small><sup>1</sup></small>) under laser irradiation for 5 minutes and natural cooling for 10 min. (d) Recycling heating profile for 5 times. (e) Plot of the cooling time <span class="italic">vs.</span> ln<img class="charmap" src="https://www.rsc.org/images/entities/char_2009.gif" alt="[thin space (1/6-em)]"/><span class="italic"></span>.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      
      
        <h3 id="sect662"><span class="b_heading">
          <span class="italic">In vitro</span> PTTRT synergistic therapy</span></h3>
        <span>Owing to its promising <small><sup>131</sup></small>I delivery efficiency and excellent photothermal conversion efficiency, CPDA-<small><sup>131</sup></small>I was chosen for further antitumor assays <span class="italic">in vitro</span>. As illustrated in <a title="Select to navigate to figure" href="#imgfig3">Fig. 3a</a>, there was no significant cytotoxicity to L929 cells after treatment with different concentrations of CPDA, even as high as 400 g mL<small><sup>1</sup></small>. To evaluate the PTT and RT effect of CPDA-<small><sup>131</sup></small>I, the 8305C cells were treated with CPDA-<small><sup>131</sup></small>I, CPDA + NIR and CPDA-<small><sup>131</sup></small>I + NIR at various concentrations and radioactivity. According to <a title="Select to navigate to figure" href="#imgfig3">Fig. 3b</a>, single therapy could not effectively inhibit the cell viability even at high radioactivity or concentration with laser irradiation. However, when treated with CPDA-<small><sup>131</sup></small>I + NIR, 8305C cell proliferation was significantly inhibited, suggesting the synergistic effect of PTT and RT. Additionally, the calculated CI value is 0.68, indicating a moderate synergistic effect between the two therapy methods. Calcein-AM and propidium iodide (PI) dual-staining assay was conducted to visualize the 8305C cells being killed by PTT and RT (<a title="Select to navigate to figure" href="#imgfig3">Fig. 3c</a>). The number of dead cells remarkably increased upon treatment with CPDA-<small><sup>131</sup></small>I + NIR, while more cells survived under the treatment of CPDA-<small><sup>131</sup></small>I or CPDA + NIR. Cells in groups of PBS with or without laser irradiation did not show effective inhibition. DNA double-strand breaks induced by <small><sup>131</sup></small>I emitted high-energy  rays are primarily responsible for radiation-induced cell apoptosis, which was assessed by staining using a -H2AX kit to further evaluate the synergistic effect (<a title="Select to navigate to figure" href="#imgfig3">Fig. 3d</a>). The groups treated using PBS with or without laser irradiation did not display immunofluorescence signals and were regarded as the control groups. Significant double-strand DNA breaks were induced by CPDA-<small><sup>131</sup></small>I + NIR compared to CPDA-<small><sup>131</sup></small>I or CPDA + NIR. To further confirm whether the cytotoxicity of CPDA-<small><sup>131</sup></small>I nanoparticles with laser irradiation is associated with apoptosis, flow cytometry was carried out and we found that the results of the apoptosis assay were consistent with those obtained using the cell counting kit-8 (CCK-8), calcein-AM/PI and immunofluorescence assays, as shown in <a title="Select to navigate to figure" href="#imgfig3">Fig. 3e</a>. Taken together, we conclude that a promising ATC cell ablation effect could be achieved by the combination of RT and PTT of CPDA-<small><sup>131</sup></small>I nanoparticles.</span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig3"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-f3_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-f3.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-f3.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 3 </b> <span id="fig3"><span class="graphic_title">(a) Cytotoxicity of CPDA at various concentrations to L929 cells (<span class="italic">n</span> = 3 each group). (b) Cell viability of 8305C cells after being treated with various doses of CPDA-<small><sup>131</sup></small>I, CPDA + NIR and CPDA-<small><sup>131</sup></small>I + NIR (NIR: 808 nm laser, 1 W cm<small><sup>2</sup></small>, 5 min) (<span class="italic">n</span> = 3 each group; ***<span class="italic">P</span> &lt; 0.001). (c) Calcein AM/PI co-staining images, (d) confocal fluorescence images of nuclear DNA fragmentation stained with -H2AX and (e) the flow cytometry data for the apoptosis of 8305C cells induced by PBS, PBS + NIR, CPDA-<small><sup>131</sup></small>I, CPDA + NIR and CPDA-<small><sup>131</sup></small>I + NIR. Dots at the lower left and right represent the living and early apoptotic cells, while at the upper right and left represent the cells in the late apoptotic and necrotic states.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      
      
        <h3 id="sect696"><span class="b_heading">SPECT/CT imaging studies and biodistribution and <span class="italic">in vivo</span> photothermal performance</span></h3>
        <span>
          <small><sup>125</sup></small>I is often used as a radionuclide imaging agent for SPECT/CT imaging due to its low-energy  ray emission. Therefore, CPDA-<small><sup>125</sup></small>I nanoparticles were alternatively synthesized to investigate the SPETC/CT imaging of 8305C tumor-bearing mice. A small-animal SPECT/CT system was used to continuously obtain images at various time points (0.5 h, 24 h, 3 d and 7 d) after the injection of 200 L CPDA-125I (200 Ci). All tumor-bearing mice were fed with cold NaI 2 days before the imaging assay for thyroid blocking. As shown in <a title="Select to navigate to figure" href="#imgfig4">Fig. 4a</a>, a strong signal was observed in the liver and intestinal tract at 30 min after the intravenous injection, implying that CPDA-<small><sup>125</sup></small>I may have been excreted out by the hepatobiliary system. Subsequently, an obvious tumor uptake of CPDA-<small><sup>125</sup></small>I was observed after 24 h post injection (p.i.), suggesting the efficient passive accumulation of CPDA-<small><sup>125</sup></small>I in tumors by the typical enhanced permeability and retention (EPR) effect. After 7 d, only a weak signal remained in the tumor and liver. To further accurately evaluate the biodistribution of CPDA-<small><sup>131</sup></small>I, the heart, liver, spleen, lungs, kidneys, muscle, skin, bone, brain and tumor were dissected from the mice and the radioactivity was measured using a gamma counter at 24 h after the injection. High radioactivity was detected in the tumor site, in which the radioactivity approached one-third of the liver uptake (<a title="Select to navigate to figure" href="#imgfig4">Fig. 4b</a>). In addition, the blood circulation of CPDA-<small><sup>131</sup></small>I was also evaluated using a gamma counter. We found that the pharmacokinetics of CPDA-<small><sup>131</sup></small>I were consistent with those of a two-compartment model. The half-lives of the first and second phase in blood circulation were determined to be 0.53  0.47 h and 9.86  3.58 h, respectively (<a title="Select to navigate to figure" href="#imgfig4">Fig. 4c</a>). These results indicated that iodine-labeled CPDA nanoparticles could passively accumulate in the tumor with high radioactivity through the EPR effect. Motivated by the excellent photothermal conversion efficiency of the CPDA nanoparticles <span class="italic">in vitro</span>, the PTT effect <span class="italic">in vivo</span> was further evaluated. 200 L of PBS and CPDA (1 mg mL<small><sup>1</sup></small>) were injected intravenously into the 8305C tumor-bearing mice <span class="italic">via</span> their tail vein, and were then treated using an 808 nm laser (1 W cm<small><sup>2</sup></small>) after 24 h for 5 min, and continuous thermographs of the mice were obtained using a thermal infrared camera. As shown in <a title="Select to navigate to figure" href="#imgfig4">Fig. 4d</a>, the treatment of CPDA + NIR could heat the tumor tissue rapidly 6 h after the injection. The temperature reached nearly 50 C in 5 min, which was much higher than that of PBS + NIR (<a title="Select to navigate to figure" href="#imgfig4">Fig. 4e</a>). These results were consistent with the experiments <span class="italic">in vitro</span>, suggesting that the CPDA nanoparticles are a type of reliable and efficient photothermal reagent <span class="italic">in vitro</span> and <span class="italic">in vivo</span>.</span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig4"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-f4_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-f4.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-f4.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 4 </b> <span id="fig4"><span class="graphic_title">(a) SPECT/CT images of 8305C tumor-bearing mice at various time points after intravenous injection with CPDA-<small><sup>125</sup></small>I; the tumors sites were circled by white dots. (b) Biodistribution (<span class="italic">n</span> = 3) and (c) blood circulation profiles of CPDA-<small><sup>125</sup></small>I in various organs measured at 24 h post injection (<span class="italic">n</span> = 3). (d) Infrared thermal images <span class="italic">in vivo</span> and (e) the temperature curves of the tumor sites after being intravenously injected with PBS and CPDA and then irradiated using an 808 nm laser at 1 W cm<small><sup>2</sup></small> for 5 min (<span class="italic">n</span> = 3).</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      
      
        <h3 id="sect730"><span class="b_heading">
          <span class="italic">In vivo</span> antitumor activity</span></h3>
        <span>The excellent SPECT/CT imaging and biodistribution outcomes encouraged us to further investigate the therapy effect of CPDA-<small><sup>131</sup></small>I for the integration of PTT and RT <span class="italic">in vivo</span>. 8305C tumor-bearing nude mice were randomly divided into five groups (<span class="italic">n</span> = 5) and treated with PBS, PBS + NIR, CPDA-<small><sup>131</sup></small>I, CPDA + NIR and CPDA-<small><sup>131</sup></small>I + NIR (<a title="Select to navigate to figure" href="#imgfig5">Fig. 5a</a>). As shown in <a title="Select to navigate to figure" href="#imgfig5">Fig. 5b</a>, all mice did not show a decreasing tendency of body weight after the 22 d treatment. The tumor growth was significantly inhibited in the group of CPDA-<small><sup>131</sup></small>I + NIR, and a single treatment of CPDA + NIR or CPDA-<small><sup>131</sup></small>I showed a markedly slower growth rate of the tumor than that of PBS or PBS + NIR (Fig. S4<a title="Select to navigate to footnote" href="#fn1"></a> and <a title="Select to navigate to figure" href="#imgfig5">Fig. 5ce</a>). Furthermore, the tumor size did not increase anymore after being treated with CPDA-<small><sup>131</sup></small>I + NIR, mainly attributed to the synergistic effect of PTT and RT on the 8305C tumors. The pathological changes and apoptosis level in the tumors were further verified by hematoxylin &amp; eosin (H&amp;E) staining and the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. The results revealed that the combination of PTT and RT displayed the greatest cytotoxicity to 8305C cells <span class="italic">in vivo</span> by inducing apoptosis (<a title="Select to navigate to figure" href="#imgfig5">Fig. 5f</a>). To evaluate the potential toxicity of CPDA-<small><sup>131</sup></small>I to the non-tumor tissues, the main organs (lungs, liver, spleen, heart and kidneys) were eviscerated from the 8305C tumor-bearing mice after 22 d, and then stained with H&amp;E. Compared with the control groups, the treated groups exhibited no significant pathological changes (Fig. S5<a title="Select to navigate to footnote" href="#fn1"></a>). Considering the components of CPDA-<small><sup>131</sup></small>I, dopamine is one of the most abundant catecholaminergic neurotransmitters in the brain, and <small><sup>131</sup></small>I is widely used in the clinic, both holding good physical safety. Therefore, different radioisotope (<small><sup>131</sup></small>I and <small><sup>125</sup></small>I)-labeled CPDA have great potential to be developed as ATC theranostic nanoplatforms with high biosafety.</span>
        <br/><div class="image_table"><table><tr><td colspan="3" class="imgHolder" id="imgfig5"><a href="/image/article/2021/NR/d1nr02892h/d1nr02892h-f5_hi-res.gif" title="Select to open image in new window" onclick="open(this.href, &#34;_blank&#34;, &#34;toolbar=1,scrollbars=yes,resizable=1&#34;); return false;"><img alt="image file: d1nr02892h-f5.tif" src="/image/article/2021/NR/d1nr02892h/d1nr02892h-f5.gif"/></a></td></tr><tr><td class="pushTitleRight"> </td><td class="image_title"><b>Fig. 5 </b> <span id="fig5"><span class="graphic_title">(a) Dosage regimen of the <span class="italic">in vivo</span> treatment for 22 days. (b) Relative body weight of the 8305C tumor-bearing mice treated with PBS, PBS + NIR, CPDA-<small><sup>131</sup></small>I, CPDA + NIR and CPDA-<small><sup>131</sup></small>I + NIR (<span class="italic">n</span> = 5; *<span class="italic">P</span> &lt; 0.05). (c) Digital photographs, (d) relative volume (<span class="italic">n</span> = 5; *<span class="italic">P</span> &lt; 0.05 and **<span class="italic">P</span> &lt; 0.01) and (e) relative weight of the tumors eviscerated from the mice after treatment (<span class="italic">n</span> = 5; *<span class="italic">P</span> &lt; 0.05 and ***<span class="italic">P</span> &lt; 0.001). (f) H&amp;E and TUNEL images of the tumor tissues in all groups, and * means <span class="italic">P</span> &lt; 0.05; scale bars: 100 m.</span></span></td><td class="pushTitleLeft"> </td></tr></table></div>
      
    
    
      <h2 id="sect768"><span class="a_heading">Conclusions</span></h2>
      <span>In summary, we successfully synthesized novel PDA nanoparticles (SPDA, PPDA, MPDA, CPDA, BPDA and APDA) with various morphologies and they were used as nanocarriers for ATC theranostics in SPECT/CT imaging guided combined RT and PTT. These PDA nanoparticles were labeled with <small><sup>131</sup></small>I by the iodogen method. Among them, CPDA-<small><sup>131</sup></small>I nanoparticles with a high specific area and cerebriform morphology were the most promising agents for the combination of PTT and RT, and show high photothermal conversion efficiency, iodine-labeling efficiency and good stability. Such CPDA-<small><sup>131</sup></small>I nanoparticles exhibited an extra impressive synergistic therapy effect on 8305C tumors <span class="italic">in vitro</span> and <span class="italic">in vivo</span> compared with PTT or RT alone. Additionally, CPDA-<small><sup>125</sup></small>I can be utilized to obtain clear SPETC/CT images of tumors and thus guide PTT and RT. Moreover, no obvious cellular toxicity of CPDA-<small><sup>131</sup></small>I was observed, confirming their great biocompatibility. Therefore, we concluded that these radioiodine-labeled CPDA nanoparticles warrant further exploration of SPECT/CT guided photothermalradio therapy of ATC in clinical practice.</span>
    
    
      <h2 id="sect778"><span class="a_heading">Conflicts of interest</span></h2>
      <span>There are no conflicts to declare.</span>
    
  
    <h2 id="sect782"><span class="a_heading">Acknowledgements</span></h2>
      <span>This research was mainly supported by the National Natural Science Foundation of China (Grant number 82001856), the authors also thanks National Key Research and Development Plan of P.R. China (Grant number2016YFA0201500), National Natural Science Foundation of China (Grant numbers 51673116, 11775143, 51690151, 21875134, 51873106, 51703126),Shanghai Municipal Government,China(Grant number18JC1410800),the Yangtze River Scholar Program (Grant numberWF221411002), 2ndInnovation Fund of Precision Medicine Union Research Center of Shanghai Jiao Tong University &amp; Southern Hospital of Sixth People's Hospital affiliated to Shanghai Jiao Tong University (Grant number2017B006), and China Postdoctoral Science Foundation (Grant number2019M661481).</span>
    
    <span id="sect784"><h2 id="sect781"><span class="a_heading">References</span></h2></span><ol type="1">
      <li><span id="cit1">J. Ljubas, T. Ovesen and M. Rusan, <span class="italic">Cancers</span>, 2019, <span class="bold">11</span>, 943<a target="_blank" class="DOILink" href="https://doi.org/10.3390/cancers11070943" title="DOI Link to resource 10.3390/cancers11070943">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BB3cXjtlCntbk%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=31277524%5Buid%5D" title="PubMed Link to resource 31277524">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/1_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit2">S. Saini, K. Tulla, A. V. Maker, K. D. Burman and B. S. Prabhakar, <span class="italic">Mol. Cancer</span>, 2018, <span class="bold">17</span>, 154<a target="_blank" class="DOILink" href="https://doi.org/10.1186/s12943-018-0903-0" title="DOI Link to resource 10.1186/s12943-018-0903-0">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXptlWnsbY%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=30352606%5Buid%5D" title="PubMed Link to resource 30352606">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/2_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit3">J. Ahn, E. Song, H. S. Oh, D. E. Song, W. G. Kim, T. Y. Kim, W. B. Kim, Y. K. Shong and M. J. Jeon, <span class="italic">Thyroid</span>, 2019, <span class="bold">29</span>, 824<a target="_blank" class="DOILink" href="https://doi.org/10.1089/thy.2018.0684" title="DOI Link to resource 10.1089/thy.2018.0684">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWgu7jN" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/3_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit4">M. J. Livhits and M. W. Yeh, <span class="italic">Clin. Thyroidol.</span>, 2017, <span class="bold">29</span>, 90<a target="_blank" class="DOILink" href="https://doi.org/10.1089/ct.2017;29.90-93" title="DOI Link to resource 10.1089/ct.2017;29.90-93">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/4_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit5">E. Molinaro, C. Romei, A. Biagini, E. Sabini, L. Agate, S. Mazzeo, G. Materazzi, S. Sellari-Franceschini, A. Ribechini, L. Torregrossa, F. Basolo, P. Vitti and R. Elisei, <span class="italic">Nat. Rev. Endocrinol.</span>, 2017, <span class="bold">13</span>, 644<a target="_blank" class="DOILink" href="https://doi.org/10.1038/nrendo.2017.76" title="DOI Link to resource 10.1038/nrendo.2017.76">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2sXhtFyitrbL" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=28707679%5Buid%5D" title="PubMed Link to resource 28707679">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/5_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit6">R. C. Smallridge, K. B. Ain, S. L. Asa, K. C. Bible, J. D. Brierley, K. D. Burman, E. Kebebew, N. Y. Lee, Y. E. Nikiforov, M. S. Rosenthal, M. H. Shah, A. R. Shaha and R. M. Tuttle, <span class="italic">Thyroid</span>, 2012, <span class="bold">22</span>, 11<a target="_blank" class="DOILink" href="https://doi.org/10.1089/thy.2012.0302" title="DOI Link to resource 10.1089/thy.2012.0302">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/6_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit7">S. N. Rao, M. Zafereo, R. Dadu, N. L. Busaidy, K. Hess, G. J. Cote, M. D. Williams, W. N. William, V. Sandulache, N. Gross, G. B. Gunn, C. Lu, R. Ferrarotto, S. Y. Lai and M. E. Cabanillas, <span class="italic">Thyroid</span>, 2017, <span class="bold">27</span>, 672<a target="_blank" class="DOILink" href="https://doi.org/10.1089/thy.2016.0395" title="DOI Link to resource 10.1089/thy.2016.0395">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2sXmvFamtb0%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=28068873%5Buid%5D" title="PubMed Link to resource 28068873">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/7_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit8">T. D. Singh, S. Y. Jeong, S. W. Lee, J. H. Ha, I. K. Lee, S. H. Kim, J. Kim, S. J. Cho, B. C. Ahn, J. Lee and Y. H. Jeon, <span class="italic">J. Nucl. Med.</span>, 2015, <span class="bold">56</span>, 1690<a target="_blank" class="DOILink" href="https://doi.org/10.2967/jnumed.115.160366" title="DOI Link to resource 10.2967/jnumed.115.160366">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC28XmslWlsbs%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26338896%5Buid%5D" title="PubMed Link to resource 26338896">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/8_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit9">D. V. Nostrand, <span class="italic">J. Nucl. Med.</span>, 2017, <span class="bold">58</span>, 697<a target="_blank" class="DOILink" href="https://doi.org/10.2967/jnumed.116.188862" title="DOI Link to resource 10.2967/jnumed.116.188862">CrossRef</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=28209908%5Buid%5D" title="PubMed Link to resource 28209908">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/9_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit10">M. Zhou, Y. Chen, M. Adachi, X. Wen, B. Erwin, O. Mawlawi, S. Y. Lai and C. Li, <span class="italic">Biomaterials</span>, 2015, <span class="bold">57</span>, 41<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.biomaterials.2015.04.013" title="DOI Link to resource 10.1016/j.biomaterials.2015.04.013">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2MXms1Gqsbk%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/10_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit11">S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L. D. Locati, K. Newbold, M. G. Papotti and A. Berruti, <span class="italic">Ann. Oncol.</span>, 2019, <span class="bold">30</span>, 1856<a target="_blank" class="DOILink" href="https://doi.org/10.1093/annonc/mdz400" title="DOI Link to resource 10.1093/annonc/mdz400">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ASTN%3A280%3ADC%252BB3Mnhs1CqsA%253D%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=31549998%5Buid%5D" title="PubMed Link to resource 31549998">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/11_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit12">O. ElMokh, V. Taelman, P. Radojewski, M. A. Roelli, A. Stoss, R. A. Dumont, M. S. Dettmer, W. A. Phillips, M. A. Walter and R.-P. Charles, <span class="italic">J. Nucl. Med.</span>, 2019, <span class="bold">60</span>, 917<a target="_blank" class="DOILink" href="https://doi.org/10.2967/jnumed.118.216721" title="DOI Link to resource 10.2967/jnumed.118.216721">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BB3cXpslaqtQ%253D%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=30464041%5Buid%5D" title="PubMed Link to resource 30464041">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/12_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit13">T. D. Singh, J. Song, J. Kim, J. Chin, H. D. Ji, J.-E. Lee, S. B. Lee, H. Yoon, J. H. Yu, S. K. Kim, G. S. Yoon, H. Hwang, H. W. Lee, J. M. Oh, S.-W. Lee, J. Lee, H.-S. Choi, S.-Y. Na, W.-I. Choi, Y. J. Park, Y. S. Song, Y. A. Kim, I.-K. Lee, S. J. Cho and Y. H. Jeon, <span class="italic">Clin. Cancer Res.</span>, 2019, <span class="bold">25</span>, 5069<a target="_blank" class="DOILink" href="https://doi.org/10.1158/1078-0432.CCR-18-3007" title="DOI Link to resource 10.1158/1078-0432.CCR-18-3007">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Gnu7rJ" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=31010838%5Buid%5D" title="PubMed Link to resource 31010838">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/13_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit14">K. A. Schmohl, P. Dolp, C. Schug, K. Knoop, K. Klutz, N. Schwenk, P. Bartenstein, P. J. Nelson, M. Ogris, E. Wagner and C. Spitzweg, <span class="italic">Thyroid</span>, 2017, <span class="bold">27</span>, 1534<a target="_blank" class="DOILink" href="https://doi.org/10.1089/thy.2017.0290" title="DOI Link to resource 10.1089/thy.2017.0290">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2sXhvFOgurbN" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=29032724%5Buid%5D" title="PubMed Link to resource 29032724">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/14_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit15">D. Luo, S. Goel, H. j. Liu, K. a. Carter, D. Jiang, J. Geng, C. j. Kutyreff, J. w. Engle, W. c. Huang, S. Shao, C. Fang, W. Cai and J. f. Lovell, <span class="italic">ACS Nano</span>, 2017, <span class="bold">11</span>, 12482<a target="_blank" class="DOILink" href="https://doi.org/10.1021/acsnano.7b06578" title="DOI Link to resource 10.1021/acsnano.7b06578">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhsLzI" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=29195037%5Buid%5D" title="PubMed Link to resource 29195037">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/15_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit16">X. Yang, L. Gao, Q. Guo, Y. Li, Y. Ma, J. Yang, C. Gong and C. Yi, <span class="italic">Nano Res.</span>, 2020, <span class="bold">13</span>, 2579<a target="_blank" class="DOILink" href="https://doi.org/10.1007/s12274-020-2722-z" title="DOI Link to resource 10.1007/s12274-020-2722-z">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BB3cXmtFSlur0%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/16_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit17">X. Yi, K. Yang, C. Liang, X. Y. Zhong, P. Ning Yao, G. S. Song, D. L. Wang, C. C. Ge, C. Y. Chen, Z. F. Chai and Z. Liu, <span class="italic">Adv. Funct. Mater.</span>, 2015, <span class="bold">25</span>, 4689<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adfm.201502003" title="DOI Link to resource 10.1002/adfm.201502003">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2MXhtVektbfF" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/17_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit18">H. Zhao, Y. Chao, J. J. Liu, J. Huang, J. Pan, W. L. Guo, J. Z. Wu, M. Sheng, K. Yang, J. Wang and Z. Liu, <span class="italic">Theranostics</span>, 2016, <span class="bold">18</span>, 1833<a target="_blank" class="DOILink" href="https://doi.org/10.7150/thno.16047" title="DOI Link to resource 10.7150/thno.16047">CrossRef</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27570554%5Buid%5D" title="PubMed Link to resource 27570554">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/18_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit19">H. Yang, J. Zhao, C. Wu, C. Ye, D. Zou and S. Wang, <span class="italic">Chem. Eng. J.</span>, 2018, <span class="bold">351</span>, 548<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.cej.2018.06.100" title="DOI Link to resource 10.1016/j.cej.2018.06.100">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1cXht1ahu73E" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/19_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit20">J. Zhao, P. Xie, C. Ye, C. Wu, W. Han, M. Huang, S. Wang and H. Chen, <span class="italic">Chem. Eng. J.</span>, 2018, <span class="bold">351</span>, 157<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.cej.2018.06.101" title="DOI Link to resource 10.1016/j.cej.2018.06.101">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1cXhtFOktLbP" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/20_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit21">X. Y. Hong, X. F. Zhong, G. S. Du, Y. Y. Hou, Y. T. Zhang, Z. R. Zhang, T. Gong, L. Zhang and X. Sun, <span class="italic">Sci. Adv.</span>, 2020, <span class="bold">6</span>, Eaa4462<a target="_blank" class="DOILink" href="https://doi.org/10.1126/sciadv.aaz4462" title="DOI Link to resource 10.1126/sciadv.aaz4462">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/21_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit22">X. S. Liu, A. Situ, Y. N. Kang, K. R. Villabroza, Y. P. Liao, C. H. Chang, T. Donahue, A. E. Nel and H. Meng, <span class="italic">ACS Nano</span>, 2016, <span class="bold">10</span>, 2702<a target="_blank" class="DOILink" href="https://doi.org/10.1021/acsnano.5b07781" title="DOI Link to resource 10.1021/acsnano.5b07781">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC28XhvV2mtb8%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=26835979%5Buid%5D" title="PubMed Link to resource 26835979">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/22_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit23">S. Saini, K. Tulla, A. V. Maker, K. D. Burman and B. S. Prabhakar, <span class="italic">Mol. Cancer</span>, 2018, <span class="bold">17</span>, 154<a target="_blank" class="DOILink" href="https://doi.org/10.1186/s12943-018-0903-0" title="DOI Link to resource 10.1186/s12943-018-0903-0">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXptlWnsbY%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=30352606%5Buid%5D" title="PubMed Link to resource 30352606">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/23_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit24">J. P. O'Neill, D. Power, C. Condron, D. Bouchier-Hayes and M. Walsh, <span class="italic">Iran. J. Med. Sci.</span>, 2010, <span class="bold">179</span>, 9<a target="_blank" class="DOILink" href="https://doi.org/10.1007/s11845-009-0364-y" title="DOI Link to resource 10.1007/s11845-009-0364-y">CrossRef</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=19662494%5Buid%5D" title="PubMed Link to resource 19662494">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/24_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit25">A. Maniakas, R. Dadu, N. L. Busaidy, J. R. Wang, R. Ferrarotto, C. Lu, M. D. Williams, G. Brandon Gunn, M.-C. Hofmann, G. Cote, J. Sperling, N. D. Gross, E. M. Sturgis, R. P. Goepfert, S. Y. Lai, M. E. Cabanillas and M. Zafereo, <span class="italic">JAMA Oncol.</span>, 2020, <span class="bold">6</span>, 1397<a target="_blank" class="DOILink" href="https://doi.org/10.1001/jamaoncol.2020.3362" title="DOI Link to resource 10.1001/jamaoncol.2020.3362">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/25_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit26">A. K. Rengan, A. B. Bukhari, A. Pradhan, R. Malhotra, R. Banerjee, R. Srivastava and A. De, <span class="italic">Nano Lett.</span>, 2015, <span class="bold">15</span>, 842<a target="_blank" class="DOILink" href="https://doi.org/10.1021/nl5045378" title="DOI Link to resource 10.1021/nl5045378">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2MXhslGisQ%253D%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=25554860%5Buid%5D" title="PubMed Link to resource 25554860">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/26_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit27">G. Song, C. Liang, H. Gong, M. Li, X. Zheng, L. Cheng, K. Yang, X. Jiang and Z. Liu, <span class="italic">Adv. Mater.</span>, 2015, <span class="bold">27</span>, 6110<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adma.201503006" title="DOI Link to resource 10.1002/adma.201503006">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOnu7nK" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/27_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit28">J. Wang, X. Pang, X. Tan, Y. Song, L. Liu, Q. You, Q. Sun, F. Tan and N. Li, <span class="italic">Nanoscale</span>, 2017, <span class="bold">9</span>, 5551<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C6NR09219E&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C6NR09219E">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/28_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit29">M. Zhang, X. Liu, Q. Luo, Q. Wang, L. Zhao, G. Deng, R. Ge, L. Zhang, J. Hu and J. Lu, <span class="italic">Chem. Eng. J.</span>, 2020, <span class="bold">389</span>, 124450<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.cej.2020.124450" title="DOI Link to resource 10.1016/j.cej.2020.124450">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BB3cXjslSht7Y%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/29_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit30">B. Guo, J. Zhao, Z. Zhang, X. An, M. Huang and S. Wang, <span class="italic">Chem. Eng. J.</span>, 2020, <span class="bold">391</span>, 123609<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.cej.2019.123609" title="DOI Link to resource 10.1016/j.cej.2019.123609">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXisVajtLvK" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/30_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit31">C. Qi, L. H. Fu, H. Xu, T. F. Wang, J. Lin and P. Huang, <span class="italic">Sci. China: Chem.</span>, 2019, <span class="bold">62</span>, 162<a target="_blank" class="DOILink" href="https://doi.org/10.1007/s11426-018-9392-6" title="DOI Link to resource 10.1007/s11426-018-9392-6">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXlvVGitr8%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/31_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit32">Y. L. Liu, K. L. Ai and L. H. Lu, <span class="italic">Chem. Rev.</span>, 2014, <span class="bold">114</span>, 5057<a target="_blank" class="DOILink" href="https://doi.org/10.1021/cr400407a" title="DOI Link to resource 10.1021/cr400407a">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2cXisVWgtro%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24517847%5Buid%5D" title="PubMed Link to resource 24517847">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/32_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit33">D. Wu, X. H. Duan, Q. Q. Guan, J. Liu, X. Yang, F. Zhang, P. Huang, J. Shen, X. T. Shuai and Z. Cao, <span class="italic">Adv. Funct. Mater.</span>, 2019, <span class="bold">29</span>, 1900095<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adfm.201900095" title="DOI Link to resource 10.1002/adfm.201900095">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/33_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit34">X. Y. Zhong, K. Yang, Z. L. Dong, X. Yi, Y. Wang, C. C. Ge, Y. L. Zhao and Z. Liu, <span class="italic">Adv. Funct. Mater.</span>, 2015, <span class="bold">25</span>, 7327<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adfm.201503587" title="DOI Link to resource 10.1002/adfm.201503587">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhtrfP" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/34_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit35">M. Farokhi, F. Mottaghitalab, M. R. Saeb and S. Thomas, <span class="italic">J. Controlled Release</span>, 2019, <span class="bold">309</span>, 203<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.jconrel.2019.07.036" title="DOI Link to resource 10.1016/j.jconrel.2019.07.036">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSgt7zO" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=31362077%5Buid%5D" title="PubMed Link to resource 31362077">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/35_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit36">Y. L. Liu, K. Ai, J. H. Liu, M. Deng, Y. Y. He and L. H. Lu, <span class="italic">Adv. Mater.</span>, 2013, <span class="bold">25</span>, 1353<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adma.201204683" title="DOI Link to resource 10.1002/adma.201204683">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC38XhvVyhs7fO" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23280690%5Buid%5D" title="PubMed Link to resource 23280690">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/36_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit37">X. Liu, J. Qin, X. Zhang, L. Zou, X. Yang, Q. Wang, Y. Zheng, W. Mei and K. Wang, <span class="italic">Nanoscale</span>, 2020, <span class="bold">12</span>, 24206<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=D0NR05732K&amp;newsite=1" title="Link to RSC resource DOI:10.1039/D0NR05732K">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/37_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit38">J.-J. Hu, Y.-J. Cheng and X.-Z. Zhang, <span class="italic">Nanoscale</span>, 2018, <span class="bold">10</span>, 22657<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C8NR07627H&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C8NR07627H">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/38_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit39">B. Zhou, Q. Wu, M. Wang, A. Hoover, X. Wang, F. Zhou, R. A. Towner, N. Smith, D. Saunders, J. Song, J. Qu and W. R. Chen, <span class="italic">Chem. Eng. J.</span>, 2020, <span class="bold">396</span>, 125239<a target="_blank" class="DOILink" href="https://doi.org/10.1016/j.cej.2020.125239" title="DOI Link to resource 10.1016/j.cej.2020.125239">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BB3cXosVyntb0%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=32523422%5Buid%5D" title="PubMed Link to resource 32523422">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/39_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit40">Y. Liu, W. Zhen, Y. Wang, J. Liu, L. Jin, T. Zhang, S. Zhang, Y. Zhao, S. Song, C. Li, J. Zhu, Y. Yang and H. Zhang, <span class="italic">Angew. Chem., Int. Ed.</span>, 2019, <span class="bold">58</span>, 2407<a target="_blank" class="DOILink" href="https://doi.org/10.1002/anie.201813702" title="DOI Link to resource 10.1002/anie.201813702">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOqsrY%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=30600877%5Buid%5D" title="PubMed Link to resource 30600877">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/40_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit41">R. Zhang, Y. Duan and B. Liu, <span class="italic">Nanoscale</span>, 2019, <span class="bold">7</span>(11), 19241<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C9NR06012J&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C9NR06012J">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/41_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit42">J. Kong, S. I. S. Shahabadi and X. Lu, <span class="italic">Nanoscale</span>, 2016, <span class="bold">8</span>, 1770<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C5NR06711A&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C5NR06711A">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/42_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit43">M. J. Zhang, L. Y. Zhang, Y. D. Chen, L. Li, Z. M. Su and C. G. Wang, <span class="italic">Chem. Sci.</span>, 2017, <span class="bold">8</span>, 8067<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C7SC03521G&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C7SC03521G">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/43_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit44">S. Huang, L. Zhang, M. Xu, C. Li, H. Fu, J. Huang, X. Jin, S. Liang and H. Wang, <span class="italic">Adv. Healthcare Mater.</span>, 2021, <span class="bold">10</span>, e2001029<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adhm.202001029" title="DOI Link to resource 10.1002/adhm.202001029">CrossRef</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=33326188%5Buid%5D" title="PubMed Link to resource 33326188">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/44_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit45">S. Xiong, Y. Wang, R. Yu, L. Chen, J. Zhu and Z. Hu, <span class="italic">J. Mater. Chem. A</span>, 2014, <span class="bold">2</span>, 7578<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C4TA00235K&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C4TA00235K">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/45_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit46">J. Zhou, Y. Jiang, S. Hou, P. K. Upputuri, D. Wu, J. Li, P. Wang, X. Zhen, M. Pramanik, K. Pu and H. Duan, <span class="italic">ACS Nano</span>, 2018, <span class="bold">12</span>, 2643<a target="_blank" class="DOILink" href="https://doi.org/10.1021/acsnano.7b08725" title="DOI Link to resource 10.1021/acsnano.7b08725">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1cXis1Kqu74%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=29438610%5Buid%5D" title="PubMed Link to resource 29438610">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/46_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit47">G. Shu, H. Wang and X. Zhang, <span class="italic">ACS Appl. Mater. Interfaces</span>, 2019, <span class="bold">11</span>, 3323<a target="_blank" class="DOILink" href="https://doi.org/10.1021/acsami.8b17418" title="DOI Link to resource 10.1021/acsami.8b17418">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1cXis1Sgtb7J" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/47_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit48">C. Dai, Y. Chen, X. Jing, L. Xiang, D. Yang, H. Lin, Z. Liu, X. Han and R. Wu, <span class="italic">ACS Nano</span>, 2017, <span class="bold">11</span>, 12696<a target="_blank" class="DOILink" href="https://doi.org/10.1021/acsnano.7b07241" title="DOI Link to resource 10.1021/acsnano.7b07241">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2sXhvVars7bK" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/48_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit49">Z. Y. Li, Y. Liu, X. Q. Wang, L. H. Liu, J. J. Hu, G. F. Luo, W. H. Chen, L. Rong and X. Z. Zhang, <span class="italic">ACS Appl. Mater. Interfaces</span>, 2013, <span class="bold">5</span>, 7995<a target="_blank" class="DOILink" href="https://doi.org/10.1021/am402082d" title="DOI Link to resource 10.1021/am402082d">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeqsbzO" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=23869943%5Buid%5D" title="PubMed Link to resource 23869943">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/49_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit50">T. C. Chou, <span class="italic">Cancer Res.</span>, 2010, <span class="bold">70</span>, 440<a target="_blank" class="DOILink" href="https://doi.org/10.1158/0008-5472.CAN-09-1947" title="DOI Link to resource 10.1158/0008-5472.CAN-09-1947">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC3cXltlWksA%253D%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/50_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit51">P. Huang, D. Wang, Y. Su, W. Huang, Y. Zhou, D. Cui, X. Zhu and D. Yan, <span class="italic">J. Am. Chem. Soc.</span>, 2014, <span class="bold">136</span>, 11748<a target="_blank" class="DOILink" href="https://doi.org/10.1021/ja505212y" title="DOI Link to resource 10.1021/ja505212y">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC2cXht1Git73M" title="Link to resource in CAS">CAS</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=25078892%5Buid%5D" title="PubMed Link to resource 25078892">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/51_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit52">L. Shi, L. Xu, C. Wu, B. Xue, X. Jin, J. Yang and X. Zhu, <span class="italic">ACS Appl. Mater. Interfaces</span>, 2018, <span class="bold">10</span>, 8555<a target="_blank" class="DOILink" href="https://doi.org/10.1021/acsami.8b00875" title="DOI Link to resource 10.1021/acsami.8b00875">CrossRef</a><a target="_blank" class="COILink" href="/en/content/coiresolver?coi=1%3ACAS%3A528%3ADC%252BC1cXjtlOlt7c%253D" title="Link to resource in CAS">CAS</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/52_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit53">P. Lei, R. An, P. Zhang, S. Yao, S. Song, L. Dong, X. Xu, K. Du, J. Feng and H. Zhang, <span class="italic">Adv. Funct. Mater.</span>, 2017, <span class="bold">27</span>, 1702018<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adfm.201702018" title="DOI Link to resource 10.1002/adfm.201702018">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/53_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit54">Q. Wei, Y. Chen, X. Ma, J. Ji, Y. Qiao, B. Zhou, F. Ma, D. Ling, H. Zhang, M. Tian, J. Tian and M. Zhou, <span class="italic">Adv. Funct. Mater.</span>, 2018, <span class="bold">28</span>, 1704634<a target="_blank" class="DOILink" href="https://doi.org/10.1002/adfm.201704634" title="DOI Link to resource 10.1002/adfm.201704634">CrossRef</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/54_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit55">S. Xiong, J. Fan, Y. Wang, J. Zhu, J. Yu and Z. Hu, <span class="italic">J. Mater. Chem. A</span>, 2017, <span class="bold">5</span>, 18242<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C7TA05880B&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C7TA05880B">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/55_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit56">Y. Xing, J. Zhang, F. Chen, J. Liu and K. Cai, <span class="italic">Nanoscale</span>, 2017, <span class="bold">9</span>, 8781<a target="_blank" class="RSCLink" href="http://xlink.rsc.org/?doi=C7NR01857F&amp;newsite=1" title="Link to RSC resource DOI:10.1039/C7NR01857F">RSC</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/56_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
      <li><span id="cit57">X. Du, C. Zhao, M. Zhou, T. Ma, H. Huang, M. Jaroniec, X. Zhang and S. Z. Qiao, <span class="italic">Small</span>, 2017, <span class="bold">13</span>, 1602592<a target="_blank" class="DOILink" href="https://doi.org/10.1002/smll.201602592" title="DOI Link to resource 10.1002/smll.201602592">CrossRef</a><a target="_blank" class="PMedLink" href="http://www.ncbi.nlm.nih.gov/pubmed/?term=27860353%5Buid%5D" title="PubMed Link to resource 27860353">PubMed</a><a target="_blank" class="URLLink" href="/en/Content/OpenURL/50001067/d1nr02892h/57_1" title="Link via OpenURL Resolver"><img height="14px" alt="" src="/en/Image/GetOpenURLImage/50001067"/></a>.</span></li>
    </ol>
    
    
    
    
    
  <hr/><table><tr><td><h3>Footnotes</h3></td></tr><tr><td><span class="sup_ref"> <span id="fn1">Electronic supplementary information (ESI) available. See DOI: <a href="http://xlink.rsc.org/?DOI=d1nr02892h" target="_blank" title="Select to resolve DOI: 10.1039/d1nr02892h">10.1039/d1nr02892h</a></span></span></td></tr><tr><td><span class="sup_ref"> <span id="fn2">These authors contributed equally to this work.</span></span></td></tr></table><table><tr><td><hr/></td></tr><tr><td><b>This journal is  The Royal Society of Chemistry 2021</b></td></tr></table></div></div></div></body><script src="/content/scripts/CrossMarkIE.js"></script><SaxonLicenceTest result="pass" message="Licenced Enterprise Edition [ EE 9.3.0.4 ]"/></html>